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Chapter 1 – GENERAL OVERVIEW 
 
 
 
The present PhD thesis will present the develompent of high sensitivity and specificity 
protein microarrays for molecular diagnostics using both fluorescence-based and label-
free detection platforms. The Chapter 2 - Introduction on Microarrays will illustrate the 
principles of this technique in protein analyses, while the following Chapter 3 will focus 
on the Optical Detection Methods used: both fluorescence-based and label-free 
detection platforms are described at the state-of-the-art. 
Advantages and limitations of the microarray technology will be depicted in Chapter 5. 
The first studies investigated on innovative approaches to improve immunoassay 
performances on solid supports, using surface immobilized hydrogels as versatile 
reagent reservoir. 
Further investigation moved towards the exploitation of fluorescent-based and label-
free microarray detection platforms in diagnostic application for early detection of 
Neurodegenerative Disorders (NDs) biomarkers. First, in Chapter 6, a high sensitivity 
immunoassay developed for Amyloid-β peptides detection on a silicon microarray 
platform is presented. Afterwards, as described in Chapter 7, the microarray platforms 
have been applied to detect whole extra-cellular nanosized vesicles, i.e. exosomes, as 
carriers of biomarkers of NDs or as biomarkers themselves. Exosomes were 
characterized according to their dimensions and physical properties using label-free 
detection and, at the same time, they were phenotyped based on protein expression 
on their surface using the fluorescence detection platform. 
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The present PhD research was carried out at the Istituto di Chimica del 
Riconoscimento Molecolare– CNR, Milan, under the supervision of Dr. 
Marcella Chiari.  
Label-free Single Particle-IRIS experiments described in Chapter 7 were 
conducted at the Electrical and Computer Engineering department at Boston 
University (MA, USA), in collaboration with Prof. S. Unlu. 
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Chapter 2 - INTRODUCTION ON MICROARRAYS 
 
 
 
2.1 - MICROARRAY TECHNOLOGY 
This dissertation focuses on the development of biosensing platforms based on protein 
microarray technology. In particular, the attention is focused on the development of 
novel diagnostic tools for the diagnosis of Neurodegenerative Disorders with high 
sensitivity and specificity. Microarray assays were developed on silicon/silicon oxide 
surfaces, coated with a polymeric film; surface binding interactions were then analysed 
with both fluorescent-based and label-free detection methods. 
 
2.1.1 – Protein Microarrays 
Microarray analyses were developed at first for DNA investigation, but in the last years 
they also gained increasing interest in proteomic studies. Over the past decade, the 
combination of two-dimensional gel electrophoresis/mass spectrometry (MS) has been 
the major tool in comprehensive proteomic studies; in this technique, the proteome is 
resolved and each spot is analyzed by MS or MS/MS. The resolution of this method is 
good enough to separate protein isoforms that are modified by post-translational 
processes (for example, phosphorylation [Kaufmann et al., 2001], glycosylation 
[Taniguchi et al., 2001], and deamination [Sarioglu et al., 2000]). However, this 
technique has some limitations, such as lack of automation of the processes involved, 
poor detection of low abundant proteins, low reproducibility, cumbersome protocols 
and difficulties in the separation of hydrophobic membrane proteins and basic or high-
molecular-mass proteins [Santoni et al., 2000; Molloy et al., 2002; Patton et al., 1999]. 
Another current approach in proteomics is the liquid chromatography (LC)/MS 
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method, in which ion-exchange, reversed-phase and affinity-based separations can be 
combined to improve the resolution of each protein species. Although these two 
technologies theoretically offer a complete coverage of the proteome, they still lack of 
parallelization and miniaturization, features that are required for high-throughput 
screening of proteins. In order to comply with these characteristics, protein microarray 
technology has emerged in last ten years [Kambhampati, 2003;Fung, 2004]. 
Microarrays can be accounted as an evolution of conventional Enzyme Linked 
ImmunoSorbent Assays (ELISA) moved toward a miniaturized scale where each well is 
turned into a single spot. The general scheme of a typical microarray experimentis 
reported in Figure 2.1 and it requires the patterning of a large set of capture ligands 
(DNA, protein or peptide probes) on a solid functionalized support using a robot 
(spotter) able to spot nano-litres of probe solutions. The probes are required to bind 
the surface and to remain stable during washing and blocking of surface unreacted 
sites. The array is then probed with a sample containing (among a variety of unrelated 
molecules) the counterparts (target) of the molecular recognition event under study. 
Usually, protein microarrays study the interaction between proteins or peptides and 
their specific antibodies. The high affinity interaction between probes and target 
molecules is monitored by another component, the transducer, which converts the 
molecular complex into a quantifiable physic signal, which often is fluorescence. 
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Fugure 2. 1 - General scheme of a typical microarray experiment. 
 
 
By using this approach, both multiplexing and miniaturization are achieved relative to 
ELISA, thus dramatically increasing the amount of data that can be obtained per 
volume of biological sample. Moreover, on each microarray support many different 
sub-arrays can be printed (Figure 2.2).  
Two different type of analyses can be performed with protein microarrays, depending 
on the purpose of the analisis. One consists of determining the abundance of proteins 
of interest in complex protein mixtures with highly specific capture agents, one for 
each target protein, for example, by antigen–antibody interactions. 
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Fugure 2. 2 - Traditional microarray format. Many subarrays can be 
printed on a conventional microscope slide. Each subarray can be 
constituted of many replicate spots patterned on specific positions. 
 
 
The other possibility is to find out the functions of proteins of interest, including 
protein–protein interactions, receptor–ligand interactions, enzymatic activities etc. 
Hence, protein arrays generally fall in one of these categories [Cretich et al., 2006]: (i) 
detection arrays (or analytical arrays) and (ii) function arrays. 
In protein detection microarrays, an array of affinity reagents (antigens or antibodies) 
is immobilized on a support and used to determine the presence and the abundance of 
the target protein in a complex matrix such as plasma or serum. Analytical arrays can 
be used to assay antibodies, for example for diagnosis of allergy [Cretich et al., 2009] 
or autoimmune diseases [Robinson et al., 2003; Balboni et al., 2006] or to monitor 
protein expression on a large scale [Phizicky et al., 2003; Zhu et al., 2003].  
In protein function microarrays (which are generally aimed at discovering protein 
function in fundamental research) a large set of purified proteins or peptides or even 
an entire proteome is spotted and immobilized. The array is then used for parallel 
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screening of a range of biochemical interactions. Protein function arrays [Blackburn et 
al., 2005] can be used to study the effect of substrates or inhibitors on enzyme 
activities [Zhu Q. et al., 2003], protein-drug or hormone effector interactions [Kim et 
al., 2005] or in epitope mapping studies [Chiari et al., 2005]. In an another kind of 
protein function arrays, usually referred as reverse phase microarrays [Zhu H. et al., 
2003], tissues, cell lysates or serum samples are spotted on a surface and probed with 
one antibody per analyte for a multiplex readout. 
 
 
2.2 – MICROARRAYS and BIOSENSORS 
Microarray technology falls in the bigger field of biosensors, which were deﬁned by 
IUPAC in 1992 as “devices that use speciﬁc biochemical reactions mediated by isolated 
enzymes, immune systems, tissues, organelles or whole cells to detect chemical 
compounds usually by electrical, thermal or optical signals” [Brandenburg et al., 2009]. 
By this definition classical biosensors are made of three components:  
1) a biological recognition component that sensitively and specifically recognizes the 
analyte;  
2) the transducer element that transforms the event of physiochemical interaction into 
another quantifiable signal;  
3) electronics and a user interface that outputs the results in an easy and user-friendly 
way.  
From this point of view, biomarkers are all kinds of quantitative parameters that can 
be obtained from a patient and that correlate to a particular disease [Bier et al., 2013], 
in a way making them key components of the biosensor tools. 
 12 
 
2.2.1 - Biomarkers 
A biological marker, or biomarker [Frey et al., 2005; Henley et al., 2005; Sprott, 2010; 
Cedazo-Minguez et al., 2010; Ho et al., 2010], is objectively measured and evaluated as 
an indicator of normal biological processes, pathogenic processes or pharmacological 
responses to a therapeutic intervention. A biomarker can serve as an indicator of 
health (i.e. biomarker of ageing) and disease. The sensitivity, speciﬁcity and ease-of-
use are the most important factors that ultimately deﬁne the diagnostic utility of a 
biomarker. Some biomarkers are more reasonably viewed as risk factors rather than 
true disease markers. In order for a diagnostic biomarker to be useful, specific criteria 
for the given status must be contemporary statisfied [Hampel et al., 2010; Desai et al., 
2005; Sjogren et al., 2003; Zetterberg et al., 2003]. 
Biomarkers can be discovered from different human tissues or liquids, such as blood, 
urine and saliva. Plasma/serum measurements are the gold standard in clinics, because 
they are minimally invasive, as compared with cerebrospinal fluid (CSF), and therefore 
easily collected and processed [Humpel, 2011]. A major advantage of blood samples is 
that patients can be followed up and screened over several years. The collection of 
other fluids (e.g. saliva, urine, fibroblasts or eye secretions) is fast, cheap and non-
invasive; however, the use of these fluids requires very sensitive methods to detect 
low-level of proteins and a well-known correlation to specific pathologies. Also CSF is a 
very useful fluid for some diagnosis (e.g. neurodegenerative pathologies), because it 
reflects metabolic processes in the brain owing to direct contact between the brain 
and CSF itself, but its diagnostic use is only limited because of invasive collection by 
lumbar puncture [Humpel, 2011]. 
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2.3 - MICROARRAY SUPPORTS 
Microarrays aim to study the molecular interactions occurring between two partners: 
one contained in a liquid sample (target molecule) and one immobilized on a solid 
support (probe). The chemistry used for the immobilization of probe molecules on the 
substrate plays a significant role in the success of any experiment [Sola, 2012]. This is 
particularly true with protein arrays, as polypeptides tend to bind to surfaces in a 
nonspecific manner, sometimes affecting their biological activity [Chiari et al., 2005]. 
The key requirements of protein microarray surfaces are [Sola, 2012]: 
(1) provision of an optimal binding capacity of capture ligands (probes); 
(2) retaining of biological activity of probes (proteins tend to unfold when immobilized 
onto a support, in order to allow internal hydrophobic side chains to form hydrophobic 
bonds with the solid surface); 
(3) accessibility of the ligand to the interaction partner (protein–surface interactions 
reduce the accessibility of the target, possibly leading to false negative results). This 
issue is particularly important for peptide microarrays due to the small molecular mass 
of capture ligands; 
(4) low degree of non-specific interaction (the achievement of a low degree of non-
specific binding is extremely difficult when the sample is a complex mixture of 
thousands of molecules such as serum). 
These requirements are of outstanding importance as the abundance of many proteins 
in animal and human plasma can be even lower than 1 pg/mL making their detection 
very problematic. Therefore the surface chemistry of the supports plays a key role in 
the development of tools compatible with a broad set of biomolecules while 
maintaining their integrity, native conformation and biological function. 
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2.3.1 - Characteristics of the Supports 
The final performance of a microarray biochip strongly depends on parameters related 
to the immobilization process itself, which include [Sola, 2012]: 
(a) the chemical and physical properties of the surface, as they influence both specific 
and non-specific binding of target and non-target biomolecules;  
(b) the density of the probes on the surface, which determines the sensitivity of the 
chip and the limit of detection, defining the distance between the immobilized probes 
and the chip surface;  
(c) the orientation of the immobilized proteins, which might impair binding, especially 
to large analytes such as proteins. 
The selection of the solid surface employed for generating microarray chip depends on 
the intended application. For example, gold surfaces are often used for the 
development of biosensors with electrochemical and surface plasmon resonance (SPR) 
read-out [Lee et al., 2005] because of their outstanding electrical conductivity and 
convenient functionalization by means of thiol chemisorption. In contrast, glass or 
silicon [Cretich et al., 2009b] is typically preferred for optical sensors because of their 
low intrinsic fluorescence and, in the case of glass, transparency. In general, these 
surfaces are characterized by their chemical homogeneity and stability, their 
controllable surface properties (such as polarity and wettability), their reactivity 
towards a wide range of chemical functionalities and the reproducibility of surface 
modification [Sola, 2012]. 
 
2.3.2 - Polymer Coating 
The reactivity of a chip surface is determined by the functional groups it displays. The 
density of the reactive groups is one important factor controlling the amount of 
protein that can be immobilized on a specific surface area and thus consequently 
influences the limit of detection attainable with the particular chip. Proteins offer 
many functional groups, mainly in the amino acid side chains, that are suitable for 
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immobilization purposes. Such functional groups can be used to covalently couple 
proteins to surfaces by a range of different reactions. To this end, more complex three-
dimensional structure that moves away from the surface and exposes the functional 
groups have been developed in M. Chiari’s laboratory at the Institute of Chemistry of 
Molecular Recognition of the National Council of the Research in Milan (ICRM-CNR) 
[Sola, 2012]. 
In an attempt to obtain a suitable polymer coating with high capacity for probes 
immobilization offering a homogeneous “natural” aqueous environment, an 
hydrophilic copolymer made by N,N-dimethylacrylamide (DMA), N-
acryloyloxysuccinimide (NAS), and 3-(trimethoxysilyl)propyl methacrylate (MAPS) 
(poly(DMA-NAS-MAPS)) firstly reported for the preparation of low-density DNA 
microarrays on glass surfaces was developed (Figure 2.3) [Pirri et al., 2004]. This 
poly(DMA-NAS-MAPS) is a ter-copolymer whose silanizing properties are due to the 
presence of the 3-(trimethoxysilyl)propyl methacrylate, that allows the stable binding 
of the polymer itself on glass or silicon surfaces. On the other side, the N-
acryloyloxysuccinimide behaves as a monomer reactive towards nucloephilic groups 
(i.e., amines) on probe biomolecules. 
Moreover, the innovative aspect of this approach relies on the fact that the polymer 
self-adsorbs onto the glass (or silicon) surface very quickly, simply by immersing glass 
slides in a diluted aqueous solution of the polymer and without time consuming glass 
pre-treatments. Therefore, the coating procedure provides a simple, fast and 
inexpensive method for producing a hydrophilic functional nanometric film surface 
bearing active esters, able to react with amino groups of modified DNA, proteins and 
peptides.  
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Fugure 2. 3 – Structure of poly(DMA-NAS-MAPS): the polymer used 
to coat silicon chips for the microarray applications described in the 
following studies. The composition of thethree monomers in the final 
copolymer is different: 97% of DMA, 2% of NAS and 1% of MAPS. 
 
 
The quality of a microarray assay is not only determined by the desired binding events 
between the target and the probe biomolecules but also, to a large extent, by the 
suppression of undesired, nonspecific binding of analytes and other components 
within the biological sample [Sola, 2012]. Such non-specific binding can give rise to 
background signals and thus to low signal-to-noise ratios and higher limits of 
detection. Although many elaborate approaches have proven to be effective for 
minimizing nonspecific adsorption, it must be clearly stated that the old fashioned 
blocking of reactive surface sites by the addition of blocking agents such as the protein 
bovine serum albumin (BSA), skim milk powder, or other reagents and the presence of 
surfactants such as Tween-20 and sodium dodecyl sulfate (SDS) are usually 
indispensable to the suppression of non-specific protein adsorption [Crowther, 1995]. 
In case of poly(DMA-NAS-MAPS) coating, before any sample incubations, silicon chips 
are blocked either with ethanolamine or BSA, to inactivate unreacted sites on the 
polymer chains, leading to a very low background. 
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2.3.3 - Silicon Surfaces for Microarrays 
The present research focused on the development of microarray tools based on optical 
detection methods, among which fluorescent-based and Interferometric Reflectance 
Imaging Sensor (IRIS) platforms. 
One of the easiest way to enhance fluorescent signals is based on optic interference, 
which takes advantage of layered materials with different refractive index to increase 
the photosorption of the fluorochromes in proximity of the surfaces thus resulting in a 
constructive interference of the reflected light onto the detector. The condition of 
constructive interference is satisfied with many kind of glass slides coated with very 
complex dielectric or metallic layers [Fouqué et al., 2005]. Glass slides are the favoured 
surfaces for microarrays thanks to their availability, cost, flatness, rigidity, 
transparency, amenability of the surface to chemical modification and non-porosity 
[Holloway et al., 2002]. 
However in last years, Cretich and colleagues introduced innovative materials for 
microarray supports, such as silicon/silicon oxide [Cretich et al., 2009b] and alluminium 
[Cretich et al., 2014]. It has been demonstrated thatthe optimized 100 nm layer of 
thermally grown silicon oxide (SiO2) with low roughness and low ﬂuorescence 
background, provides ﬂuorescence intensiﬁcation due to the constructive interference 
between the incident and reﬂected waves of the ﬂuorescence radiation [Cretich et al., 
2009b]. Polymeric coatings, such as the poly(DMA-NAS-MAPS), with nanometric 
thickness, does not appreciably alter the optical properties of the silicon oxide, 
conferring to the surfaces optimal binding speciﬁcity, thus leading to a high signal-to-
noise ratio. [Cretich et al., 2009b]. Moreover, the techniques chosen for both substrate 
production and surface modification are simple, inexpensive, and amenable to mass 
production. The novel Si/SiO2 surfacecoated with poly(DMA-NAS-MAPS) provided a 5- 
to 10-fold enhancement of the ﬂuorescence signals in comparison to commercial glass 
slides, thus providing higher sensitivity in analytes detection (Figure 2.4) [Cretich et al., 
2009b]. 
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Fugure 2.4 - The silicon chips with a top layer of 100 nm oxide provided a 5 to 10-fold 
enhancement of the ﬂuorescence signals in comparison to commercial glass slides, thus 
providing higher sensitivity in analytes detection. a) Silicon chip used for fluorescence 
detection: white square evidence the 100 nm silicon oxide layer thickness. b) Layers of well 
defined thickness act as interference layers and reflect, towards the detector, the light that 
would be otherwise absorbed by the substrate. c) Fluorescence enhancement on reflecting 
substrates at normal incidence of excitation and collection. The simulations for excitation (blu 
line), emission (red line) and total collected intensity enhancement (black line), via utilization 
of the layered reflecting substrate for varying thickness of the top transparent oxide layer are 
shown. Monochromatic excitation at 543nm, and collection in the 550-600nm range are 
assumed [Yalcin et al., 2009]. 
 
 
By varying the thickness of the SiO2 layer, it is possible to enhance the emission of any 
fluorophore of choice by constructive interference with significant improvements in 
detection sensitivity [Cretich et al., 2011] and to employ the Interferometric 
Reflectance Imaging Sensor (IRIS), a platform amenable to high-throughput screening 
for label-free multiplexed detection [Monroe et al., 2011]. Respectively, 100 nm silicon 
oxide thickness is optimal for fluorescence-labelling detection, while a thickness of 500 
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nm is required for the label-free IRIS one. Thankfully, silicon technology and tuned 
modulation of the oxide layer facilitate dual detection of label-based and label-free 
detection schemes on a single chip. The possibility to detect changes in a spot on a 
single chip using two complementary detection approaches is of immense utility 
during the assay development process, providing information which is generally not 
available in glass microarray technology but crucial for determining the consistency 
and quality of the spotted array, quantifying the amount of immobilised probes and 
detecting the fluorescence of bioassays.  
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Chapter 3 - OPTICAL DETECTION METHODS 
 
 
 
The detection of protein in microarray technology is mainly based on optical 
measurements. Available methods can be divided in two categories: the label-based 
and the label-free detection platforms. 
 
 
3.1  – Label-based detection methods 
Detection methods based on labeled-probes have been developed and adapted from 
immunoassay protocols and require the use of fluorescently labeled, chromogenic or 
chemiluminescent molecules in order to detect analytes bound to the surface. As 
described in Cretich et al., 2006, microarrays can be classified into two categories: (i) 
function arrays and (ii) detection arrays (or analytical arrays). Function arrays use a 
direct detection method (Figure 3.1, a), where a protein mixture is immobilized on a 
proper surface and then detected by labelled specific antibodies. Analytical arrays can 
be further classified according totheassay protocol used as indirect and sandwich 
detections (Figure 3.1, respectively b and c). In both cases capture biomolecules are 
immobilized on a proper surface and subsequently incubated with the sample. Indirect 
detection requires the straight labeling of the target biomolecules, while sandwich 
assays necessitate a secondary labeled antibody which interacts with a different 
epitope on the same target protein [Espina et al., 2004]. In this latter case, the 
combination of two binding events for the detection of a single analyte increases the 
specificity of the analysis. However, this approach might be less sensitive because of 
increasing working steps. 
 21 
 
 
Fugure 3.1 - Label-based microarray detection methods [Espina et al., 2004]. a) 
Direct detection: the analyte is printed on the surface and probed with labeled 
targets; b) Indirect detection: the labeled analyte is captured by probes arrayed 
on the surface; c) Sandwich assay: the analyte is first captured by probes bound to 
the surface and then detected by labeled secondary antibodies against a different 
epitope on the same protein. 
 
   
3.1.1 – Chromogenic Labels 
Chromogens are compounds that can be converted to a dye or a pigment through an 
enzymatic reaction (e.g. oxidation). In microarray technologies, they are employed as 
substrate of enzymes covalently bound to detection antibodies. The most commonly 
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used enzymes are the horseradish peroxidase (HRP) and the alkaline phosphatase (AP), 
both able to act on many kinds of substrates. Depending on the chromogen employed, 
the signal intensity might be different. However, in all cases the coloured product 
precipitates in correspondence of the spot and is often visible by naked eye. The 
higher the colour intensity, the higher concentration of target biomolecule in the 
sample. 
 
3.1.2 - Chemiluminescent Labels 
Microarrays detection methods based on chemiluminescence reactions are adapted 
from Western blotting protocols. Also in this case, detection antibodies are covalently 
bounded to enzymes (e.g. HRP or AP), but the oxidation of a different substrate such 
as luminol, elicits a prolonged light emission. Emitted photons can be captured by X-
ray films, phosphorous plates or more commonly by a CCD camera. Non-specific 
signals are prevented thanks to opportune buffer solutions, usually containing diluted 
bovine serum albumin (BSA) or casein. Although very sensitive, chemiluminescence 
has low resolution due to small spot size and limited dymanic range [Schweitzer et al., 
2003]. 
 
3.1.3 - Fluorescent Labels 
Nowadays, the fluorescent label method has become the gold standard for microarray 
detection. A lot of fluorochromes have been developed in order to enhance brightness 
and stability. Many molecules are available on the market, such as fluorescein, 
Cyanine, AlexaFluor, rodamine, acridine, ficobiliproteins and Bodipy. These molecules, 
characterized by stability in a large range of pH values, have narrow peaks of 
excitation/emission spectra, whose tunability provides multicolour assay schemes 
[Angenendt et al., 2005]. The fluorescent molecules are chosen based on the sample 
properties, spectra emission and type of support used. In fact, not all surfaces or 
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supports are compatible with fluorescence detection, due to auto-fluorescence 
phenomena. Moreover, the sample itself may contain molecules which interferes with 
the signal emission, as it happens in the case of flavoproteins whose emitted light has 
the same wavelengths range of fluorescein dye. 
Cyanine-3 (Cy3) and Cyanine-5 (Cy5) are the most wide-spread used fluorochromes as 
they can be used to screen simultaneously for two different targets without any 
overlapping in emission spectra. In fact, Cy3 absorbs green light at 550 nm wavelength 
and emits at 570 nm, while Cy5 absorbs and emits red light, respectively at 649 and 
670 nm. The N-hydroxysuccinimide (NHS) esters of these dyes react with covalently 
bound primary amines on arginine and lysine residues on proteins or peptides, 
rendering them fluorescent. Moreover, the high interest for these molecules is also 
due to the very low photobleaching, which means that fluorescence performance does 
not decrease after prolonged exposure to a light source. In the following studies 
described in this PhD thesis, label-based microarray detection was always based on the 
use of Cyanine fluorescent dyes, whose signals were revealed through a confocal laser 
scanner. 
 
 
3.2 – Label-free detection methods 
For every label-based detection approach, the production and selection of specific 
antibodies (or ligand biomolecules) as well as their labelling is still a major problem. 
Moreover, miniaturized technologies, such as microarrays, designed to detect low 
sample concentrations, required the development of ad-hoc protocols for signals 
amplification in order to increase sensitivity and signal-to-noise ratios. The added 
value of label-free detection techniques lies on the prevention of any kind of 
interference in the signal due to the presence of the dye itself. However, label-free 
platforms require sophisticated and expensive equipments, which are limited to 
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laboratory applications and are not always available in clinical settings. Moreover, up 
to now, the sensibility of these methods is still lower than label-based detection 
devices. 
The most popular label-free detection methods for proteins are: mass spectrometry 
(MS), surface plasmonic resonance imaging (SPR) and atomic force microscopy (AFM). 
However, all these approaches share the limit of not being applicable to detect signals 
from microarray tools. To overcome this problem, a label-free imaging technique using 
photonic crystals for both qualitative and quantitative spot analysis was developed 
[Ozkumur et al., 2008] by S. Unlu laboratory at the Boston University (MA, USA) and 
successfully applied to both DNA and protein microarrays without altering standard 
microarray protocols. In this simple interferometric method, the optical phase-shift 
resulting from the surface accumulation of biological mass at different binding sites is 
monitored to investigate molecular interactions [Ozkumur et al., 2008]. The so called 
Interferometric Reflectance Imaging Sensor (IRIS) is an innovative label-free platform 
which provides high sensitivity, even up to single particle detection. Moreover, it is 
amenable to high-throughput screening for label-free multiplexed detection [Monroe 
et al., 2011]. According to the amplitude of optical magnification two application can 
be achieved: measurement of biomaterial massed on the surface as consequence of 
binding events (conventional IRIS) or detection of nanostructures such as single 
particles (SP-IRIS). 
 
3.2.1 - Interferometric Reflectance Imaging Sensor (IRIS) 
IRIS is a platform technology for the high-throughput screening of biomolecular 
interactions on a solid surface, that aims to measure total biomass gathered on each 
spot operating on the base of optical interference. IRIS platform requires a silicon 
support with a thermally grown 500 nm silicon oxide layer on top of which probe 
molecules are spotted in an array format. The detectionprinciple is based on 
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quantifying the shifts in the spectral reﬂectance signature to calculate the added 
biomass by sampling it at speciﬁc wavelengths and measuring the characteristic 
reﬂection intensities using a CCD camera (Retiga 2000R from QImaging) [Cretich et al., 
2011b]. The sensor surface is sequentially illuminated using an ACULED VHL surface-
mount LED package (Perkin-Elmer), which has four independently driven LEDs with 
peak emission wavelengths of 455, 518, 598 and 635 nm. When light incident to a 
layered surface reflects off the interfaces, it undergoes interference due to the 
refractive index variation of various layers and acquires a spectral signature. In IRIS, 
the principle of detection for total biomass is based on quantifying the shifts in the 
spectral reflectance curve due to accumulation of biomass on the chip (Figure 3.2). 
After acquiring images of the substrate for each of the four wavelengths, each pixel of 
the CCD represents an individual measurement of the reﬂective interference intensity 
at each wavelength, forming a 3-dimensional array of data (pixel, wavelength, 
intensity) for the entire sensor. The data points for each pixel are ﬁtted to a curve 
derived using Fresnel equations, which govern the behaviour of reﬂection from a semi-
transparent bi-layered substrate [Daaboul et al., 2010; Cretich et al., 2011b]. 
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Fugure 3.2 - IRIS detection method [Daaboul et al., 2010]. Panel (a) displays the shift of the 
reflectivity curve due to 5nm step increases in thickness on the surface. The colored Gaussians 
represent the 4 LEDs used to sample the curve. Picture (b) outlines the sensor’s imaging path, 
illustrating biomass accumulation dependent grayscale intensity changes. Image (c) shows an 
example of the sensor’ssurface with an array of protein spots. Theheight profile along the blu 
dashed line in across spots is then shown in panel (d). 
 
 
To maintain the simplicity of the system without sacriﬁcing sensivity, an on-chip 
reference is utilized [Vedula et al., 2010]. The reference is created by including a non-
interfering region, such as a region etched to the bare silicon, within the ﬁeld of view 
(Figure 3.3). 
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Fugure 3.3 – Silicon chip used for IRIS detection: 
a) region of 500 nm silicon oxide layer thickness; 
b) non-interfering reference region. 
 
 
Information related to every pixel in each image are at first fitted using a custom-made 
algorithm written in MATLAB software, then the surface topography of the sensor’s 
surface is presented in a grey scale image where brighter regions indicate greater 
thickness on the surface (see Figure 3.2, panel c). To determine optical spot heights, 
the average value from pixels in an annular region outside of the spot (background) is 
subtracted from the average value of pixels inside the spot. By using previously 
determined calibration factors, this information can be converted to mass densities at 
each spot location on the chip to determine the binding [Özkumur et al., 2009]. 
Özkumur et al. proved that this technique is quantitative by directly relating the 
measured optical thickness of the biolayers to the absolute amount of molecules on 
the surface. They demonstrated that 1 nm of optical thickness correlates to an 
absorbed mass conversion factor of 1.21 ng/mm2 for BSA, 1.28 ng/mm2 for IgG and 0.8 
ng/mm2 for DNA [Özkumur et al., 2009]. 
Moreover, the silicon technology and the tuned modulation of the oxide layer allow 
the fabrication of supports with areas bearing both 100 and 500 nm silicon oxide 
layers, thus providing the possibility of dual detection of label-based and label-free 
detection schemes on a single chip [Cretich et al., 2012]. The possibility to detect both, 
mass and fluorescence, changes in a spot on the samesupport is of immense benefit 
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during the assay development process to characterise the quality and the quantity of 
spotted reagents. This information, which is generally not available in glass microarray 
technology, is crucial for determining the consistency and quality of the spotted array. 
By knowing the amount of immobilised probes it is possible to correlate the 
fluorescence detected to the actual mass on the surface which, due to the minute 
amounts of probe spotted, varies considerably from one experiment to another [Gagni 
et al., 2013]. 
 
3.2.2 - Single Particle-IRIS (SP-IRIS) 
Single Particle-IRIS (SP-IRIS) is the latest evolution of the conventional IRIS platform, 
developed to enable digital detection of nanoparticles (NP) on surface with unique 
orthogonal verification via size/shape discrimination and minimal sample preparation. 
By increasing the magnitude of the numerical aperture of the same IRIS optical lenses, 
SP-IRIS is amenable to detect and characterize NPin the single particle limit [Yurt et al., 
2012]. This opportunity is useful to understand NP behaviour and to develop devices 
for diagnostic applications. Despite the signiﬁcant progress in the last decade in the 
development of novel methods for single NP detection, their characterization still 
remains a challenge for most practical applications. For istance, the analysis of 
nanoparticles with different shape, size or chemical composition in heterogeneous 
solutions requires speciﬁc detection principles to classify the NP of interest in a 
complex population. Recent techniques for label-free detection and characterization of 
individual nanoparticles are based on electrical, mechanical, optical and microscopic 
principles, which include surface plasmon resonance (SPR) and interferometric 
microscopy [Yurt et al., 2012]. 
Interferometric microscopy applied to the study of nanoparticles is based on the 
illumination of NP with a coherent or incoherent visible light source and probing the 
light scattered or absorbed by the nanoparticles using free-space optical elements 
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such as objective lenses and array/single-element detectors [Yurt et al., 2012]. For a 
small spherical nanoparticle, the scattered intensity at a detector, at a given 
wavelength of light, depends on the dielectric index of both NP and surrounding 
medium as well as on the radius of the NP themselves [van de Hulst, 1981]. The strong 
dependence of the scattered intensity on the particle size makes smaller nanoparticles 
difﬁcult to detect. One approach useful to overcome this issue relies on mixing the 
weak scattered ﬁeld with a stronger reference ﬁeld [Yurt et al., 2012]. In this way,the 
phase angle difference between reference and scattered ﬁelds gains a very important 
role [Plakhotnik et al., 2001; Ignatovich et al., 2006]. Furthermore, the strong 
reference field contributes as a constant background intensity, while the weak 
scattered field usually vanishes for small NP because of its dependence on the sixth 
power of the particle radius. By combining all together these three data, the dominant 
optical response of the nanoparticle is given [Yurt et al., 2012]. 
Interferometric techniques were initially applied to the characterization of single 
plasmonic metallic nanoparticles [Boyer et al., 2002; Lindfors et al., 2004] as well as 
dielectric synthetic and natural ones. The optical properties of dielectric nanoparticles 
differ from the metallic ones [Yurt et al., 2012] because dielectric NP do not exhibit 
distinct spectral resonances in the visible spectral region and, moreover, they provide 
a low index contrast to the background which makes the detection more difﬁcult. 
More recently, the interferometric detection was demonstrated for gold nanoparticles 
(Au-NP) ﬁxed on a glass substrate, reaching a detection down to 5 nm in diameter 
[Lindfors et al., 2004; Jacobsen et al., 2006; Zuchner et al., 2008; Failla et al., 2006]. In 
other studies, higher order laser beams have been utilized to differentiate 
nanospheres and nanorods for which the orientation was also accurately determined 
[Zuchner et al., 2008; Failla et al., 2006]. Despite the increased sensitivity, the 
dimension-based analysis of the nanoparticles was limited due to the double valued 
optical response curve of the nanoparticles as a function of dimension [Lindfors et al., 
2004; Zuchner et al., 2008]. Using the SP-IRIS platform, Daaboul and colleagues 
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circumvented this ambiguity in sizing due to non-unique optical response by using a 
layered reﬂective substrate [Daaboul et al., 2010]. The principle of detection for SP-
IRIS is based on the enhanced contrast in the scattering signal from particles on 100 
nm silicon oxide layer, thermally grown on silicon supports. To detect and size NPs, IRIS 
shines a single green light beam (518 nm) from visible LED sources (using the same 
ACULED VHL surface-mount LED package, Perkin-Elmer, adopted for conventional IRIS 
measurements) on NPs bound to the sensor surface. Scattered beams are collected by 
a CCD camera. Acquired images are processed and fitted by a custom-made algorithm 
on MATLAB software which provides the total number of count nanoparticles per 
diameter range. Interference of light reflected from the sensor surface is modified by 
the presence of particles producing a distinct signal that reveals the size of the particle 
itself. In this approach the dielectric layered structure acts as an optical antenna 
optimizing the elastic scattering characteristics of NPs for sensitive detection and 
analysis. The instrument is set for low-index dielectric particles with diameters of 60 to 
200 nm and metallic (Au and Ag) NPs with diameters ranging from 20 to 100 nm [Yurt 
et al., 2012]. At Boston University, the group of Prof. Unlu demonstrated the 
identification of virus particles in complex samples for replication-competent wild-type 
vesicular stomatitis virus (VSV), defective VSV, and Ebola- and Marburg-pseudotyped 
VSV. Size discrimination of the imaged NPs (virions) allows differentiation between 
modified viruses having different genome lengths and facilitates a reduction in the 
counting of non-specifically bound particles to achieve a limit-of-detection (LOD) of 
5E+03 pfu/mL (< 10 atto-molar of viable virus) for the Ebola and Marburg VSV pseudo-
types. In that approach, they have demonstrated the simultaneous detection of 
multiple viruses in serum or whole blood as well as in samples contaminated with high 
levels of bacteria [Daaboul et al., 2014]. By employing affinity-based capture, size 
discrimination, and a “digital” detection scheme to count single virus particles, they 
showed that a robust and sensitive virus/NP sensing assay could be established for 
targets in complex samples.  
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Chapter 4 – AIM OF THE WORK 
 
 
 
Several application of protein microarray technology in diagnostics have been 
published and a limited number of protein microarrays is currently available on the In 
Vitro Diagnostics (IVD) market. Albeit several advantages, related to the 
miniaturization, the multiplexing capability and the possibility of integrating the 
immunoassays in biosensing devices, microarrays may still lack of specificity or 
sensitivity. To overcome these limitations and expand the use of protein microarray 
platform in diagnostics, the present PhD research aimed at developing innovative 
approaches to increase the assay specificity and sensitivity, reaching very low 
detection limits, that are compatible with the use of the proposed devices in 
diagnostics. Furthermore, the use of protein microarrays has been applied to the 
characterization of emerging biomarkers: exosomes. 
First of all, surface immobilized hydrogels have been investigated as reagent reservoir 
for microarray reagents. They have been demonstrated to store reagents in a dry form, 
stable over days, in a format easy to transport and to preserve. Moreover, they also 
acted as chambers able to physically separate analytes or reagents which may cross-
react with proteins on the printed arrays. In this way the solution was prevented from 
spreading over the surface and the assays provided sentitive performances, 
comparable to standard static incubations. 
In further studies, the complementarity of information provided by fluorescence-
based, label-free IRIS and SP-IRIS microarray platforms has been applied to develop 
immunoassays useful in the diagnostics of Neurodegenerative Disorders. Specifically, 
two different assay formats have been exploited. The first part of the work focused on 
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the development of a classical sandwich immunoassay able to detect physiological 
concentrations of Amyloid-beta peptides, biomarkers for Alzheimer’s disease, in both 
artificial cerebrospinal fluid and real human samples.  
The second study was aimed at extending the concept of protein microarrays to 
extracellular vesicles (i.e., exosomes) detection through surface antigen-antibodies 
recognition. In this innovative application, the nanoparticles were detected with label-
free IRIS (total biomass measurements) and SP-IRIS (particle counting and size 
distribution). In addition, individual particles were incubated with gold-labeled 
antibodies to identify biomarkers expressed on their surface. 
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Chapter 5 – INNOVATIVE APPROACHES TO IMPROVE PROTEIN 
MICROARRAY PERFORMANCES: Surface Immobilized Hydrogels as 
Versatile Reagent Reservoir for Microarrays 
 
 
 
In the last decade, protein microarrays have been adopted to investigate protein 
expression patterns and the function of the entire proteome [Kung et al., 2009], to 
identify biomarkers in serum [Bohm et al., 2011] and to predict evolution of cancer 
disease [Carlsson et al., 2011]. Despite their huge potential, protein microarrays still 
have not revolutioned routinary human diagnostics because many technical and 
operational challenges hinder their application in clinical settings [Ellington et al., 
2010]. The major obstacle in the development of protein microarrays is due to the 
complexity of protein-based interactions. Unlike the predictable sequence-specific 
hybridization chemistry of DNA arrays, proteins exhibit an extraordinary wide range of 
structures and mutual affinities [Gaster et al., 2011]. 
Among all, protein microarrays based on immunoassay format gain higher specificity in 
binding events, thanks to the antigen-antibody interaction. However, in many cases, 
this high specificity implicates the ability of other molecules with structural similarity 
or identical epitopes to bind to the same antibody. This competition is known as as 
cross-reactivity and mainly takes place when polyclonal antibodies (pAbs) are used to 
capture or detect target antigens in a given sample. pAbs are an etherogeneous 
mixture of immunoglobulines (usually belonging to the IgG family) against many 
epitopes on the same protein antigen. Examples of several non-specific interactions 
that take place during microarray assays are depicted in Figure 5.1. 
 34 
 
Figure 5.1 –Several interactions that may take place during immunoassays. The first picture on 
the left represents the ideal test, when specific interactions happen between the antigen and 
both capture as well as detection antibodies. In other cases, depicted on the right, false 
positive signals can be revealed, due to non-specific binding events which may occour between 
capture and detection antibodies, non-specific antigen with the probe, different antigens in 
the same sample solution or the antigen and another detection antibody. 
 
 
A way to prevent cross-reactivity is by using monoclonal antibodies (mAbs), which are 
a homogeneous pool of IgGs all able to recognize the same single epitope on the target 
antigen. Moreover, this trick can be combined with the more specific approach of two-
site (or sandwich) assay that requires two distinct epitopes on the antigen to be 
recognized, greatly decreasing cross-reactivity even though sometimes it is not enough 
to fully eliminate this kind of interference [Diamandis et al., 1996]. The Enzyme Linked 
ImmunoSorbent Assay (ELISA) immunoassay is the gold standard for protein profiling, 
as the contemporary binding of the target analytes to both capture and detection 
antibodies yields greater specificity than using a direct detection approach.However, in 
most of microarray based multiplex assays the detection antibodies are used in 
mixture, leading to cross-reactivity events between non-matched pairs of antibodies. 
This effect increases background noise, thus affecting sensitivity and causing false 
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positive results [Ellington et al., 2010]. The accuracy of microarray-based 
immunoassays depends on the elimination or, at least, the minimization of antibody 
cross-reactivity, but the development of multiplex immunoassays on a planar 
microarray format usually requires extensive validation and a complex development 
processes [Gonzalez et al., 2008]. Moreover, when dealing with multiplex sandwich 
assays, the number of required antibody pairs increases with the number of analytes, 
making unfeasible to increase the number of assays. Whenever cross-reactivity 
happens, assay components need to be physically separated. For instance, 
Schneiderhan-Marra and colleagues proposed a multiple bead-based assay 
[Schneiderhan-Marra et al., 2010] to separate microarray reagents. Otherwise, Pla-
Roca and colleagues took advantage from a different assay set-up which let them co-
localize both capture and detection antibodies trough two sequential spotting sessions 
on precise spot coordinates. This precise localization of antibodies allowed to deliver 
detection antibodies specifically to the locations of the matched capture antibodies 
[Pla-Roca et al., 2012]. However, up to now, multiplex sandwich assays have only been 
used simultaneously for tens of targets [Pla-Roca et al., 2012; Djoba Siawaya et al., 
2008]. Recently, the SnapChip method, introduced by Li and colleagues, was 
demonstrated to solve the problem of cross-reactivity in multiplex immunoassay [Li et 
al., 2012], using detection antibodies, spotted on a “transfer slide”, that are 
transferred at once by snapping on an “assay slide” with capture antibodies and 
antigens. Though interesting, this approach is limited by the spot volume in the 
amount of material to be transferred. 
To overcome the problem of detection antibodies cross-reactivity, the use of hydrogels 
as a versatile method to create compartments for parallel analysis in microarrays was 
investigated. The hydrogels were polymerized using a 4% w/v N,N-dimethylacrylamide 
and 3% w/v bisacrylamide solution, thus generating large pore sizes to allow the facile 
transfer of intact, functional biomolecules. The hydrogel microenvironments were 
desiccated and rehydrated with solutions containing the microarray reagents [Sola et 
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al., 2013]. During the incubation step, hydrogel plugs were placed on the 
corresponding subarray printed on the microarray support to allow entrapped 
reagents to face the capture biomolecules (Figure 5.2). 
 
 
 
Figure 5.2 – Example of immunoassay using hydrogel plugs to 
confine microarray reagents. The plugs, rehydrated with detection 
antibodies, are faced to the corresponding capture biomolecules 
arrayed on the silicon support. 
 
 
 
Hydrogel compartments are versatile reservoirs that can be used to avoid cross-
reactivity by separating single detection antibodies. For example, the detection of 
Staphylococcus aureus enterotoxins A and B was used to demonstrate how hydrogel 
plugs prevent cross-reactivity. In fact,the detection antibodies selected in this work are 
a good example of cross-reacting reagents. 
Furthermore, it has been found that there are other advantages on the use of hydrogel 
plugs, besides overcoming cross-reactivity. The versatility of hydrogel plugs makes 
them useful microarray reagent reservoirs. For istance, the hybridization with gel plugs 
rehydration requires few microliters of sample. This is advantageous when low 
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incubation volumes are available.Embedding the analyte solution in the plug and 
contacting the surface allows to use lower volumes. In particular, an immunoassay for 
the HIV p24 antigen detection has been chosen to demonstrate the equivalence in 
sensitivity when using either hydrogel plugs or standard incubation conditions.Due to 
the low limits of detection required by clinical assays for infectious disease diagnostics, 
sensitivity is of paramount importance in this assay [Sola et al., 2013]. Another 
interesting application lies on the use hydrogel plugs as containers of the calibration 
standards required for accurate quantifications or for long-term reagent storage in dry 
conditions (Figure 5.3). For example, interleukin 10 detection has been selected to 
demonstrate accuracy in quantification when using an integrated calibration curve 
since evaluation of cytokine expression levels is a critical step in biomarker discovery 
and development process [Sola et al., 2013]. 
 
 
Figure 5.3 - Hydrogel plugs used as containers of calibration standards 
required for accurate quantifications. Gels are rehydrated with a 
solution containing desired microarray reagents; plugs are then 
desiccated for long-term reagent storage in dry conditions. 
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5.1 - MATERIALS AND METHODS 
5.1.1 - Materials 
Phosphate saline buffer (PBS), Trizma base (Tris), HCl, ethanolamine, NaCl, Tween-20, 
ammonium sulfate, N,N-dimethylacrylamide (DMA), 3-(trimethoxysilyl)-
propylmethacrylate (MAPS), ammonium persulfate (APS), tetramethylethylenediamine 
(TEMED) and N,N’-methylenebisacrylamide (Bis), Staphylococcus aureus enterotoxins A 
and B (SEA and SEB) and their respective capture rabbit polyclonal antibodies were 
purchased from Sigma-Aldrich (St. Louis, MO, USA).  
Cyanine-3 labelled Streptavidin (SA-Cy3), goat anti rabbit IgG labelled with Cy3 (anti-
Rabbit IgG Cy3) and rabbit IgG were obtained from Jackson Immunoresearch (West 
Grove, PA, USA). Mouse monoclonal antibodies respectively against SEA and SEB were 
purchaised from HyTest (Turku, Finland), while labelling kit with fluorophores Cy3 and 
Cy5 was obtained from GE Healthcare (Buckinghamshire, UK).  
Both capture and biotin-labeled mouse monoclonal antibodies against HIV-p24 antigen 
as well as the peptide itself were a gift from DiaPro s.r.l. (Milan, Italy). 
Interleukin 6 (IL-6) and interleukin 10 (IL-10) ELISA kits were from BioLegend 
(SanDiego, CA). The kits provided respectively standards of IL-6 or IL-10 together with 
the corresponding capture and biotin-labeled detection antibodies against the 
interested protein.  
Silicon oxide slides were bought from Silicon Valley Microelectronics (Santa Clara, CA, 
USA). Multiwell cell culture slides were purchased from Grace Bio-labs (Redmond, OR).  
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5.1.2 - Coating of microarray slides with poly(DMA-NAS-MAPS) 
Poly(DMA-NAS-MAPS)-coated silicon microarrays were simply fabricated by immersing 
the silicon supports for 30 min in a poly(DMA-NAS-MAPS) solution (1% w/v in 0.9 M 
(NH4)2SO4). The chips were then rinsed with deionized (DI) water, dried with nitrogen 
and finally cured for 15 min under vacuum at 80 °C [Cretich et al., 2009b]. 
 
5.1.3 - Fabrication of hydrogel plugs 
Multiwell cell culture system slides were used to compartmentalize eight hydrogel 
plugs onto the same slide (Figure 5.4). Each slide was pre-treated with oxygen plasma 
for 10 min, then the silanization solution was prepared by dissolving MAPS in toluene 
at a final concentration of 10% v/v and aliquots (30 μL) of this solution were added to 
each well. Slides were stored in a chamber saturated with toluene vapor for 30 min, 
washed with acetone, dried with nitrogen and cured in a vacuum oven at 80 °C for 30 
min. A DMA-Bis solution (4% T, 3% C) was prepared by diluting a stock solution (20% T, 
3% C) in DI water, where: 
% T = [grams(acrylamide + methylenebisacrylamide)/total volume]×100; 
% C = [grams(methylenebisacrylamide)/grams(acrylamide + bis-acrylamide)]×100.  
Moreover, 40% w/v APS and TEMED were added to give a final concentration of 5 
μL/mL for both components. The monomer solution (30 μL) was immediately loaded 
into each well and polymerized for 30 min at room temperature. After polymerization 
the slides were washed twice with DI water (10 min each) and with a solution of 1% 
v/v glycerol in DI water for 10 min on a shaker. The excess water was removed by 
evaporation with nitrogen, and the hydrogel plugs were finally dried in a vacuum oven 
at room temperature. The dry hydrogel plugs were rehydrated simply by filling the 
wells with a volume of solution containing the protein of interest [Sola et al., 2013]. 
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Figure 5.4 - Picture of the multiwell system used to 
compartmentalize eight hydrogel plugs. The 
hydrogels are made of a DMA-Bis solution (4% T, 3% 
C) that can be dessiccated and rehydrated in 60 min 
by adding 30 uL of desired slution [Sola et al., 2013]. 
 
 
5.1.4 - Microarray experiments: compartmentalization of secondary antibodies 
Rabbit polyclonal antibodies against Staphylococcus aureus enterotoxin A (SEA) and 
enterotoxin B (SEB), together with streptavidin labeled with Cyanine 3 (SA-Cy3) as a 
reference were patterned on each silicon chip using a SciFlexArrayer S5 spotter from 
Scienion (Berlin, Germany) according to the scheme reported in Figure 2.3. The printed 
chips were placed in a humid chamber and incubated overnight at room temperature. 
The chips were then blocked with 50 mM ethanolamine in 1 M Tris/HCl (pH 9) for 1 h, 
washed with DI water and dried with nitrogen. Then, the chips were incubated for 2 h 
with a protein solution made of a mixture of 100 ng/mL SEA and 10 ng/mL SEB. The 
chips were washed with the washing buffer (50 mM Tris/HCl (pH 9), 0.25 M NaCl, 
0.05% v/v Tween 20) for 10 min while stirring and next rinsed with DI water. 
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The standard incubation protocol required an incubation step with a drop of target 
solution on the array followed by an incubation with a mixture of labeled secondary 
monoclonal antibodies at 1 μg/mL each in the incubation buffer (50 mM Tris–HCl, 150 
mM NaCl and 0.02% Tween 20) for 1 h. The mouse monoclonal antibody against SEA 
was labeled with Cy5, whereas the mouse monoclonal antibody against SEB was 
labeled with Cy3. 
Differently, the hydrogel-mediated incubations required the rehydration of plugs with 
20 μL of a single labeled antibody at 1 μg/mL in the incubation buffer. In this way the 
antibodies were compartmentalized in separate plugs, as shown in Figure 5.5. Each 
plug was placed in contact for 1 h with the corresponding sub-array patterned on the 
chip. After removal of the plugs, the chips were washed with PBS (10 min) and DI 
water (10 min). 
Fluorescence imaging was performed by a ProScanArray scanner from Perkin Elmer 
(Boston, MA); the silicon slides were analyzed using 90% photomultiplier (PMT) gain 
and laser power. The fluorescence intensities of 12 replicated spots were averaged. 
 
5.1.5 - Microarray experiments: HIV-p24 assay 
Four arrays of the capture antibody against HIV-p24 and SA-Cy3 as a reference were 
spotted on each chip. The printed chips were placed in a humid chamber and 
incubated at room temperature overnight. The chips were then blocked with 50 mM 
ethanolamine in 1 M Tris/HCl (pH 9) for 1 h, washed with DI water and dried with 
nitrogen. 
DMA hydrogel plugs were rehydrated for 1 h with 20 or 10 μL of the HIV-p24 antigen 
solutions at 0, 1, 2, and 5 ng/mL in the incubation buffer. Each array on the silicon 
chips was incubated for 2 h, by contacting the corresponding hydrogel plug with the 
printed array. At the same time, the control chips were incubated according to the 
conventional static protocol, with 20 μL of the HIV-p24 antigen solutions at at the 
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same concentrations for 2 h. The chips were then washed with the washing buffer for 
10 min while stirring, rinsed with DI water, and incubated with 100 μL of 1 μg/mL 
biotinylated secondary antibody against HIV-p24 in incubation buffer for 1 h in static 
conditions. The chips were washed with PBS (10 min) and DI water (10 min) and 
incubated with 100 μL of 1 μg/mL SA-Cy3 in PBS for 1 h. The chips were washed again 
with PBS (10 min) and DI water (10 min). 
Fluorescence signals were detected using a ProScanArray scanner from Perkin Elmer 
(Boston, MA); the silicon chips were analysed using 90% photomultiplier (PMT) gain 
and laser power. A calibration curve was created using the fluorescent intensities 
obtained and the limit of detection (LOD) was extrapolated from the fluorescent value 
of blank samples plus three standard deviations (3σ). Three replicates of each 
experiment were performed. 
 
5.1.6 - Microarray experiments: calibration curve 
Eight arrays of the capture antibody against interleukin 10 (IL-10) and SA-Cy3 as a 
reference were patterned on a silicon slide using a SciFlexArrayer S5 spotter according 
to the scheme reported in Figure 5.8. The printed slide was placed in a humid chamber 
and incubated overnight at room temperature. The slide was then blocked with 50 mM 
ethanolamine in 1 M Tris/HCl (pH 9) for 1 h, washed with DI water and dried with 
nitrogen. 
Six of the eight hydrogel plugs were hydrated with 20 μL of the incubation buffer 
containing 1 μg/mL of the biotinylated detection antibody against IL-10 together with 
0, 2, 5, 10, 20 or 40 ng/mL of IL-10 (BioLegend, San Diego, CA) to obtain the calibration 
curve. The dried plugs were stored at 4 °C. Upon use, the two remaining plugs were 
rehydrated with sample solutions of 3 and 10 ng/mL of freshly prepared IL-10 with 1 
µg/mL of biotinylated detection antibody in incubation buffer. Simultaneously, the six 
plugs, already containing the detection reagents, were simply rehydrated by adding DI 
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water for 1 h. The silicon-arrayed slide was incubated for 2 h at room temperature on 
the corresponding rehydrated hydrogel plugs. The slide was then washed with the 
washing buffer for 10 min while stirring, rinsed with DI water and incubated with 1 
μg/mL Cy3-streptavidin in the incubation buffer for 1 h. The slide was then washed 
with PBS (10 min) and DI water (10 min). Fluorescence visualization was performed by 
a ProScanArray scanner; the slide was analyzed using 90% photomultiplier (PMT) gain 
and laser power. The fluorescence intensities of nine replicated spots were averaged. 
Multiwell cell culture system slides with fifty wells were used for the fifty-plug format. 
The assay was performed according to the same protocol described above, now using 
IL-6 ELISA kit. Calibration mixtures were composed of 0, 2, 5, 10, 50 ng/mL IL-6 with 1 
µg/mL biotinylated detection antibody. Fluorescence detection was performed by a 
ProScanArray scanner; the slides were analyzed using 70% photomultiplier (PMT) gain 
and laser power. The fluorescence intensities of 8 spots from 50 or 10 replicated gel 
plugs were averaged. 
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5.2 - RESULTS AND DISCUSSION 
5.2.1 - Compartments for secondary antibodies 
The cross-reactivity between capture and detection antibodies is one of the most 
critical issues when developing multiplex sandwich immunoassays. To prove how 
hydrogel-plugs can prevent antibody cross-reactivity, the detection of S. aureus 
enterotoxins A and B (SEA and SEB) was investigated using a fluorescence-based 
analytical microarray platform. 
According to the standard microarray incubation protocol, the sample contacts a slide 
on which two polyclonal capture antibodies have been arrayed. Then, the analytes, in 
the present case the SEA and SEBtoxins, are detected with a mixture of their 
fluorescently-labeled monoclonal antibodies. The specificity of the detection 
antibodies selected in this work is poor. In fact, the SEA detection antibody cross-
reacts with SEB and its capture antibody, whereas the SEB detection antibody slightly 
interacts with SEA and its capture probe. 
To overcome this issue, hydrogel plugs to confine the detection antibodies were 
exploited. Figure 5.5 outlines the scheme of the assay using hydrogel-plugs under 
study. In particular, the capture antibodies for SEA and SEB were spotted on the same 
slide in two separate sub-arrays. The entire slide was then incubated with the sample 
containing either SEA, SEB or both of them, and afterwards the toxins were revealed 
using the two detection antibodies confined in the different hydrogels. Printed sub-
arrays of each capture antibody were aligned with the corresponding hydrogel plugs, 
which were in turn rehydrated either with the anti-SEA antibody labeled with Cy5 or 
with the anti-SEB antibody labeled with Cy3 in the incubation buffer. 
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Figure 5.5 - Scheme of the Staphylococcus aureus enterotoxins A and B (SEA and SEB) 
detection assay. The sample was incubated on a microarray spotted with two 
polyclonal capture antibodies. The toxins were then detected with a mixture of the 
two monoclonal detection antibodies. To overcomecross-reactivities, the capture 
antibodies for SEA and SEB were spotted in two separate sub-arrays. The entire area 
of the microarray slide was then incubated with the sample, and toxins were 
revealed using the two detection antibodies confined in different hydrogel plugs 
[Sola et al., 2013]. 
 
 
The spotting scheme and the fluorescence results are reported in Figure 5.6. In panel 
a, the fluorescence of the reference standard assay, using a mixture of the SEA and SEB 
detection antibodies, is shown. The array was first incubated with a solution containing 
a mixture of SEA (100 ng/mL) and SEB (10 ng/mL), as previously described, and then 
with a mixture of the two monoclonal detection antibodies in the incubation buffer at 
1 μg/mL. The Anti-SEA antibody was labeled with Cy5, and the anti-SEB antibody was 
labeled with Cy3. The specific signals originating from the capture and detection 
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antibody sandwiches are clearly visible on the left sub-array of the Cy5 channel for SEA 
and on the right sub-array of the Cy3 channel for SEB. The cross-reacting antibody 
signals, Cy3 anti-SEA on anti-SEB and Cy5 anti-SEB on anti-SEA, are also visible on the 
left sub-array of the Cy3 channel and right sub-array of the Cy5 channel, respectively. 
When the antibodies are labeled with the same fluorophore (as in most assays), it is 
not possible to distinguish this type of non-specific binding from a real toxin detection 
event, leading to false positive results [Sola et al., 2013]. 
On the contrary, Figure 5.6, panel b displays the fluorescence detection results, using 
the hydrogels to confine the detection antibodies, as described above. Because the 
toxins on the surface were contacted only by their specific detection antibodies, only 
the signals from those detection antibodies were observed, and the non-specific, 
cross-reactivity fluorescence was prevented. 
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Figure 5.6 - Spotting scheme and dual channel detection of SEA and SEB. a) Fluorescence 
detection of the assay performed using a mixture of the SEA and SEB detection antibodies. 
The specific signals originating from the perfect match between capture and detection 
antibodies mediated by the toxin are clearly visible on the left sub-array of the Cy5 channel 
for SEA and on the right sub-array of the Cy3 channel for SEB. However, the cross-reacting 
antibody signals, are visible as well for each sub-array on the same chip, as highlighted in 
the rectangle. b) Fluorescence detection of the assay performed using hydrogel-plugs to 
confine the detection antibodies: in this case, the labeled detection antibodies were 
entrapped in hydrogel plugs facing the corresponding sub-arrays on the slide. Specific toxin 
signals are clearly visible on the left sub-array of the Cy5 channel for SEA and on the right 
sub-array of the Cy3 channel for SEB, whereas nonspecific fluorescence, originating from 
antibody cross-reactivities, is not detectable (as highlighted in the rectangle) [Sola et al., 
2013]. 
 
 
5.2.2 - Compartments for samples 
The hydrogel plugs prevent liquid spreading on the microarray surfaces. By rehydrating 
the hydrogel with the target solution, the liquid is entrapped into the gel fibers. Gel 
plugs of defined shape provides a way to increase its local concentration, resulting in 
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improved signal intensities.In a standard microarray experiment, the target solution 
covers the entire surface, including unspotted areas. Concentrating the sample in a 
specific zone of the slide reduces the volume consumption and thus the cost per 
experiment [Sola et al., 2013]. Moreover, multi-well formats are commercially 
available for parallel analysis of multiple samples; however, they rely on the use of 
hydrophobic patterning, adhesive silicon chambers or microplates to be used in 
combination with multiple wells. Differently, hydrogel compartments can be used to 
incubate calibration standards together with the unknown sample at the same time on 
a single device, leading to higher quantitation accuracy [Sola et al., 2013]. In order to 
achieve this goal, to demonstrate the concept, hydrogel compartments were applied 
to a sandwich immunoassay for the HIV-p24 antigen detection. It was shown that using 
a conventional incubation method with the target in solution provided results that 
were identical to those obtained with the desiccated hydrogel-plaques rehydrated 
with the sample solution right before the incubation [Sola et al., 2013]. 
The assay was performed using poly(DMA-NAS-MAPS)-coated silicon slides on which 
capture anti-p24 monoclonal antibodies (1 mg/mL) were patterned. The slides were 
incubated for 2 h with 20 μL of HIV-p24 antigen dissolved in the incubation buffer 
either in standard static incubation (drop on the entire chip surface) or with 
rehydrated hydrogel-plugs. In this case the analyte was embedded in gel plugs, while 
to detect the captured antigen, a conventional incubation method with the detection 
antibody was performed in both cases. Several antigen concentrations were assayed 
from 0 to 5 ng/mL, and calibration curves (reported in Figure 5.7) were built to 
extrapolate the limits of detection (LODs). The LOD values provided by both incubation 
protocols, were 37 pg/mL with the conventional incubation method and 45 pg/mL with 
hydrogel-plugs. These values were similar, thus demonstrating that both tests provide 
similar sensitivity. Moreover, it was noticed that when using 6 mm diameter hydrogel 
plugs, a reduction of rehydration volume from 30 to 10 μL did notaffect the sensitivity 
of the assay, allowing the use of a reduced sample volume. 
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5.2.3 - Integrated calibration curves 
Another interesting application of hydrogel-plugs consists of using them as reservoirs 
of calibrations standards and reagents [Sola et al., 2013]. Indeed, storing reagents in 
dry-form represents a useful way to maintain their stability without using 
refrigeration.This simplifies assay automation, thus improving repeatability. It also 
reduces training requirements and facilitates integration into lab-on-chip devices 
[Stevens et al., 2008]. In order to prepare the storage hydrogels, the reagents solutions 
at required concentrations were used to rehydrate dry plugs, which were then 
desiccated and stored. Immediately before usage, the hydrogels were rehydrated 
simply with DI water and used in the assay. 
To demonstrate the feasibility of the method, a sandwich immunoassay for interleukin 
10 (IL-10) detection with an integrated calibration curve was carried out. A picture of 
Figure 5.7 - Calibration curves used to calculate the limits of detection (LODs) for HIV-p24 
antigen when using either standard incubation (red dots) or hydrogel plugs (blue diamonds).  
Curves led to LOD of 37 pg/mL for standard incubation and 45 pg/mL for incubation with gel 
plugs. 
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the hydrogel compartments and the spotting scheme is reported in Figure 5.8. In this 
experiment, an eight-plug format was empolyed. Six of the eight hydrogels (from a to 
f) contained the standard mix for the calibration curve (0, 2, 5, 10, 20 or 40 ng/mL IL-10 
and 1 µg/mL biotinylated detection antibody), while the remaining two plugs (g and h) 
were rehydrated with samples of unknown concentration immediately defore the 
assay. The slide bearing the hydrogels was stored in dry form. Before use, the 
calibration hydrogels were rehydrated with water while the empty hydrogels were 
rehydrated with two samples to be assayed (plug g and h, respectively at 10 and 3 
ng/mL) together with the biotin-labeled detection antibodyboth dissolved in the 
incubation buffer. The IL-10 capture antibody was spotted in 8 replicate sub-arrays on 
a coated silicon slide, placed in contact with the hydrogel compartments for 1 h. 
Washing steps and incubation with Cy3-labeled streptavidin were carried out as 
described in previous assays. The fluorescence results obtained for the calibration 
standards and the two testing samples are shown on the right side of Figure 5.8. 
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Figure 5.8 - Picture of the hydrogel plugs and spotting scheme. Six of the eight 
hydrogel plugs (from a to f) contained a standard mix for a calibration curve (IL-10 
and the biotinylated detection antibody) while the hydrogel plugs g and h were 
used to assay unknown samples. The IL-10 capture antibody was spotted in eight 
replicated sub-arrays that were placed in contact with the hydrogel plugs. The 
right panel reports the resulting fluorescence signals. 
 
 
The calibration curve reported in Figure 5.9 was obtained by incubating the arrays with 
the calibrating hydrogel plugs (blue dots). The mean fluorescence signals of the 
samples g (10 ng/mL IL-10) and h (3 ng/mL IL-10) were found to be 8524 Relative 
Fluorescence Intensity (RFI) (standard deviation, SD = 1773) and 3849 RFI (SD = 682) 
(red dashes). According to the calibration curve generated using the concentrations 
from 0 to 20 ng/mL, the signals were quantified as 11.14 ng/mL and 2.27 ng/mL, 
respectively. 
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Figure 5.9 - Calibration curve based on fluorescent signals obtained on arrays from a to e 
(blue dots). The fluorescence of array f was not included because it was out of the linear 
range. Samples in arrays g and h (red dashes) provided fluorescence signals equal to 
8524 ± 1773 RFI and 3849 ± 682 RFI. According to the calibration curve, these signals 
were quantified as 11.14 ng/mL and 2.27 ng/mL, respectively. 
 
 
Moreover, the scalability of this approach was also tested using a fifty-hydrogel plugs 
format to demonstrate its usefulness in high-density microarray technology. Figure 
5.10 (panel a) shows a picture of a 50-multiwell cell culture system where the 50 gel 
plugs were re-hydrated with a Bromophenol Blue solution [Sola et al., 2013]. 
To demonstrate the feasibility of this format, a sandwich immunoassay for interleukin 
6 (IL-6) detection was carried out. Figure 5.10 (panel b) reports the fluorescence 
results of a slide where each of the 50 gel plugs was re-hydrated with 7 μL of 50 ng/mL 
IL-6 solution. The fluorescence value from the 8 spots on 50 arrays was evaluated using 
70% laser power and PMT gain. The resulting overall average intensity was 29582 ± 
3589 RFI, thus revealing a good reproducibility of the device. 
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Moreover, using the same 50-gel plugs format, ten calibration curves for interleukin 6 
(IL-6) were perfomed simoultaneously. The assay was carried out in a fashion similar to 
te one described above, but in this case the gel plugs were re-hydrated with 7 uL of the 
standard mixutres for the calibration curve (0, 2, 5, 10, 50 ng/mL IL-6 and 1 µg/mL 
biotinylated detection antibody). Ten gel per each condition were tested. The 
fluorescence signals from the 8 spots assayed in the same condition (corresponding to 
10 gel replicates) were evaluated and averaged. The resulting calibration curve, shown 
in Figure 5.10 (panel c), displays a good degree of linearity corroborating the stability 
of this assay format. 
 
 
 
 54 
 
Figure 5.10 – Multiplexing of the system and calibration curve. a) Picture of the 
multiwell system used to compartmentalize fifty hydrogel plugs re-hydrated 
with a Bromophenol Blue solution. b) Fluorescence results obtained with a 
slide in contact with the calibration plugs in which IL-6 was spiked at 
concentrations of 50 ng/mL. c) Calibration curve based on fluorescent signals 
obtained from 10 replicates of each calibration mixtures (0, 2, 5, 10, 50 ng/mL 
IL-6 and the biotinylated detection antibody at 0.001 mg/mL). 
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5.3 - CONCLUSIONS 
In this work, the role of antibody-based microarrays specificity and selectivity was 
investigated. The specificity of binding events depends on eliminating or at least 
minimizing cross-reactivity events that take place whenever capture or detection 
antibodies bind to epitopes with similar structures aberrantly. To overcome this issue, 
compartments for detection antibodies and soluble microarray reagents were 
developed. The containers are made of hydrogels immobilized on a silicon slide or chip 
facing the corresponding sub-array on the printed surface. Moreover, these hydrogels 
were used as reagents reservoir as in each plug proteins can be stored and transported 
in a dry form, but not irreversibly trapped due to the gel porosity [Sola et al., 2013]. 
Hydrogels define a highly aqueous environment because they are about 97% 
water.Within the array, they are physically compartmentalized and fully functional. 
According to Holmes and Stellwagen [Holmes et al., 1991], the pore size of a 
polyacrylamide hydrogel strongly depends on the concentration of the acrylamide 
monomer (%T) and of the bisacrylamide cross-linker (%C). At a fixed concentration of 
cross-linker, the apparent pore radius decreases from 140 to 20 nm while % T is 
increased from 3 to 10%. In this work, the hydrogels were made of DMA (4% T) cross-
linked with Bis (3% C). The low monomer concentration was used to facilitate the 
protein diffusion and to increase the transfer efficiency. DMA was chosen thanks to its 
greater stability compared to polyacrylamide in order to create round hydrogels with a 
diameter of 6 mm, covalently attached to a glass slide to facilitate their handling [Sola 
et al., 2013]. Surface attached hydrogels can therefore be used as a versatile tool for 
the compartmentalization, storage and transport of soluble microarray reagents, 
providing performances comparable to standard incubation protocols. 
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Chapter 6 - High Sensitivity Immunoassay for Amyloid-beta 
Detectionon on a Silicon Microarray platform 
 
 
 
In the second study presented in this thesis, a high sensitive immunoassay for the 
detection of the Alzheimer’s disease (AD) biomarker Amyloid-β 1-42 (Aβ(1-42) or 
Aβ42) using both fluorescence-based and label-free IRIS microarray platforms was 
developed [Gagni et al., 2013]. 
Alzheimer’s disease (AD) is a widespread pathology associated with aging and 
classified in the major group of Neurodegenerative disorders (ND), which includes also 
vascular dementia (VD), Parkinson's disease (PD), frontotemporal lobar degeneration 
(FTLD), Lewy body dementia (LBD) and amyotrophic lateral sclerosis (ALS). These 
disorders are characterized by a progressive loss of function of specific groups of 
neurons in different regions of the brain and they are variably associated with 
dementia, personality changes, language abnormalities or progressive muscle 
weakness [Cretich et al., 2013]. Although strategies to prevent or delay the 
accumulation of the protein aggregates associated with these diseases have been 
proposed, at present, there is no perspective cure or preventive treatment for brain 
damage [Klafki et al., 2006]. In fact, NDs processes are initiated long before the clinical 
symptoms become obvious and proceed for years in a slow and irreversible manner. 
Therefore, the early diagnosis of NDs and the efficient discrimination between 
disorders is of paramount importance in order to provide effective treatments. 
Alzheimer's disease is a progressive and fatal neurodegeneration process, clinically 
characterized by progressive cognitive decline, for which currently there are no 
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available treatments to prevent or slow down the pathology evolution [Cretich et al., 
2013]. The treatment of AD is signiﬁcantly hampered by the lack of easily accessible 
biomarkers that can detect the presence of the disease reliably. At present, biomarkers 
in collected fluids (such as blood/plasma or cerebrospinal fluid) from patients only 
provide indications of the disease stage because they are not robust predictors of 
disease progression or treatment response [Henriksen et al., 2014]. Deﬁnitive 
diagnosis requires both clinical assessment of the disease and post-mortem 
veriﬁcation of the AD pathology (plaques and tangles). A probable diagnosis of AD can 
be established with more than 90% conﬁdence, based on the combination and 
integration of several clinical criteria, including medical history, physical examination, 
laboratory tests, neuroimaging and neuropsychological evaluation. An accurate early 
diagnosis of AD is still difﬁcult because early symptoms are shared by a variety of 
disorders, which reﬂects common neuropathological features. An ideal biomarker 
would distinguish AD from other types of dementia, such as mild cognitive impairment 
(MCI), or mixed forms of dementia, such as vascular dementia (VD), frontotemporal 
lobe dementia (FTLD), or Lewy body dementia (LBD) [Humpel, 2011]. Concerning this 
topic, Shneider and colleagues compared the accuracy of traditional biomarkers from 
CSF with neuroimaging in terms of both early and selective diagnosis of AD and other 
NDs, demonstrating the similarity of the obtained results in ranking patients 
[Schneider et al., 2009]. 
 
 
Figure 6.1 – Aminoacidic sequence of the Amyloid-β (1-42) peptide. 
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Abnormal extracellular accumulation of Amyloid peptides observed in the brains of AD 
patients consists predominantly of the Aβ(1-42) (Figure 6.1), that is a peptide derived 
from the proteolytic cleavage of a larger Amyloid Precursor Protein (β-APP). Figure 6.2 
shows the pathways of APP processing. The activity of α and β-secretase release the 
soluble fractions of APP, respectively sAPPα and sAPPβ, accordin to a physiological 
mechanism. Whenever APP is cleaved by γ-secretase, the Amyloid-β peptide is 
released in the extracellular medium.In healthy individuals, Aβ is found in CSF and 
plasma as a soluble monomer at sub-nanomolar concentrations.  
 
 
 
 
Figure 6.2 – APP processing release of Amyloid-β peptides [www.jci.org]. 
 
 
However, Amyoid peptides exist in several isoforms that differ at the amino or carboxy 
terminus, whose heterogeneity is particularly interesting. In vitro, the longer peptide 
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Aβ(1–42) aggregates magnitudes of order faster than the short forms Aβ(1–40) and 
Aβ(1–39) [Seilheimer et al., 1997]. Aβ(1–42) has a high propensity to form oligomers 
evenin vitro, which decreases its detection efficiency and makes accurate evaluation of 
the Limit of Detection (LOD) very difficult. Aβ42 is a difficult peptide to work with, in 
the sense that its aggregation properties are highly sensitive to sequence, purity and 
preparation conditions. The actual monomeric peptide concentrations in the 
commercial samples are largely unknown [Ammar et al., 2013]. 
The identiﬁcation and validation of biomarkers for early and specific diagnosis of AD is 
of huge importance. The measurement of a single biomarker widely varies between 
studies [Fagan et al., 2012], but the evaluation of a panel of biomarkers increases the 
diagnostic accuracy [Cretich et al., 2013]. The main source of AD biomarkers is the 
cerebrospinal fluid (CSF), as it directly reflects brain metabolic processes. However, 
lumbar puncture is an invasive and delicate procedure, restricted to patients with 
significant symptoms and is not applicable for widespread screening [de Almeida et al., 
2011; Schneider et al., 2009]. For this reason, many researches are moving towards the 
discovery and validation of novel biomarkers in easily collectible samples, such as 
plasma/serum [Cretich et al., 2013]. Biomarker signatures are under study through the 
use of proteomics, metabolomics, and gene expression studies. However, their 
reproducibility across different cohorts of patients is lacking [Snyder et al., 2014]. 
Many studies focused on novel biomarkers in plasma proteomics and lipidomics, in 
trascriptome, microRNA, autoantibodies and blood-derived genetic markers to 
discriminate AD from other NDs, but a large scale validation is still required [Henriksen 
et al., 2014]. 
At state-of-the-art, established and well-characterized biomarkers of AD from CSF are 
only Amyloid-β 1-42 peptide (Aβ1–42), total tau protein, and hyperphosphorylated tau 
protein [Cummings, 2011; Blennow et al., 2010]. To date, the combined ELISA 
measurement of the given three biomarkers in CSF is the most advanced and accepted 
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method to diagnose probable AD with high speciﬁcity and sensitivity [Blennow et al., 
2010; Hampel et al., 2007]. In addition, these biomarkers have also shown prognostic 
potential because they were able to separate subjects with mild cognitive impairment 
(MCI) who progressed to AD from those who did not [Hampel et al., 2007; Mattsson et 
al., 2009]. 
More speciﬁcally, CSF levels of Aβ(1-42) are lower in AD patients than in normal 
controls, reﬂecting amyloid precipitation. Speciﬁcally, low CSF Aβ(1-42) levels are 
detected in preclinical disease stages and predict future cognitive decline and 
neurodegeneration [Blennow et al., 2010; Buchhave et al., 2012; Ringman et al., 2012]. 
An Aβ(1-42) concentration of less than 500 pg/mL (0.1 nM) is indicative that this 
peptide is accumulating in the plaques and no more soluble in the CSF (Table 6.1T) 
[Humpel, 2011]. Changes of Aβ-levels in CSF differ based on the disease (Table 6.2T) 
[Zetterberg et al., 2010; Stefani et al., 2005; Noguchi et al., 2005]. For example, 
decreased Aβ(1–38) levels correlate with FTLD, while low Aβ(1–37) levels are 
associated with LBD [Cedazo-Minguez et al., 2010]. 
 
 
Table 6.1T - Established biomarkers in CSF used to diagnose ADa [Humpel, 2011]. 
Biomarker Controls (pg/mL) AD (pg/mL) 
Aβ(1-42) 794 ± 20 < 500* 
Total tau 
136 ± 89   (21-50 years) 
243 ± 127 (51-70 years) 
341 ± 171 (> 71 years) 
b 
> 450 
> 600* 
Phospho-tau-181 23 ± 2 > 60* 
  a Data obtained using the Innogenetics single 96-well ELISA kits. 
  b Not relevant for sporadic AD 
  * p < 0.001 
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Table 6.2T - Changes in the level ofestablished CSF biomarkers in different central nervous 
system diseases (-, no change; ↑, increase; ↓, decrease) [Humpel, 2011]. 
Disease Aβ(1-42) Total tau Phospho-tau-181 
Acute stroke - ↑(↑) - 
Alcohol dementia - - - 
AD ↓ ↑ ↑ 
CJD ↓↓ ↑↑↑ - 
Depression - - - 
FTLD ↓ ↑ - 
LBD ↓ ↑ ↑ 
Neuroinflammation ↓ - - 
Normal aging - - - 
Parkinson’s disease - - - 
VaD ↓(↓) ↑ - 
 
 
 
Interestingly, CSF levels of shorter Aβ(1–40) form are unchanged or increased in AD. 
Sunderland and Schoonenboom have therefore suggested that the Aβ(1-42)/Aβ(1-40) 
ratio can improve AD diagnosis, but others have not found such changes [Sunderland 
et al., 2004; Schoonenboom et al., 2005]. A meta-analysis by Koyama and colleagues, 
examined plasma levels of Aβ(1-42) and the ratio of Aβ(1-42)/Aβ(1-40) as predictors of 
dementia and AD. They argued that a decrease of the Aβ(1-42)/Aβ(1-40) ratio in 
plasma is a statistically signiﬁcant and clinically meaningful predictor of subsequent 
cognitive decline [Koyama et al., 2012]. Also Lewczuk et al. measured cerebrospinal 
ﬂuid (CSF) concentrations of amyloid Aβ(1-40) and Aβ(1-42) peptides, and total tau 
(tTau) protein by ELISA in order to compare their accuracy in discriminating patients 
with Alzheimer’s disease (AD), non-Alzheimer dementia (nAD) and control subjects 
(CON). As compared to the other groups, the concentrations of Aβ(1-42) and tTau 
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were, respectively, decreased and increased in AD, while Aβ(1-40) did not differ 
signiﬁcantly among the groups. According to all compared groups the peptides ratio 
Aβ(1-42)/Aβ(1-40) classiﬁed more patients correctly, as compared to the 
concentration of Aβ(1-42) alone. Moreover, the percentage of correctly classiﬁed 
patients was further improved when the Aβ ratio was combined with the analysis of 
the tTau concentration [Lewczuk et al., 2004]. Conversely Perez and colleagues 
suggested the use of other Aβ species, particularly Aβ(1-17), for the diagnosis of AD. In 
particular, they demonstrated that the ratio of free to cell-bound Aβ(1-17) in blood 
was able to discriminate between healthy individuals from patients with MCI or mild 
AD, with high sensitivity and speciﬁcity [Perez et al., 2012]. 
To date, most of the Aβ(1-42) assays rely on immunochemical detection [Cullen et al., 
2012] such as the conventional ELISAs, electrochemiluminescence-based ELISAs or the 
bead-based methods [Kang et al., 2012]. One of the most widely used assays for Aβ(1-
42) is the INNOTESTs ELISA from Innogenetics NV. It has been cited in numerous 
publications and has been recently validated and optimised leading to a lower limit of 
quantitation of 375 pg/mL [Cullen et al., 2012]. However, it is well known that ELISA 
tests lack multiplexing capability, whereas the best way to distinguish AD from other 
NDs is by using a combination of the three overmentioned biomarkers. To this end, an 
xMAP-Luminex platform that utilises the Innogenetics AlzBio3 immunoassay reagents, 
was developed to analyse AD biomarkers in CSF using 150 µL of sample, 10 handling 
steps and a total analysis time of 19 h for three targets [Kang et al., 2012]. Recently, an 
immuno-sensing platform for Aβ(1-42) based on a silane-modiﬁed silicon wafer and 
ﬂuorescence microscopy set-up has been developed with a limit of detection (LOD) of 
300 ng/mL [Ammar et al., 2013]. Signal enhancement in antibody microarrays using 
quantum dots for the screening of the potential AD biomarker Apolipoprotein E (ApoE) 
has been demonstrated with LODs up to 62 pg/mL [Morales-Narvaez et al., 2012].  
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In this context, because of the multiplexing capability, low volume sample 
consumption and sample-to-result time, microarrays are ideal tools, provided they 
have high sensitivity and speciﬁcity. However, no high-sensitivity microarray-based 
methods for Aβ(1-42) detection have been developed as yet. To fill this gap, the 
present research aimed to develop a highly sensitive immunoassay based on a 
microarray platform that utilize silicon/silicon oxide (Si/SiO2) substrates for the 
detection of the AD biomarkers Aβ(1-40) and Aβ(1-42) in artificial cerebrospinal fluid 
(ACSF) and real human samples [Gagni et al., 2013]. Prior to immunoassay 
development, the Aβ(1-42) aggregation status was evaluated by circular dichroism 
(CD) and an optimal antibody pair was selected based on the speciﬁcity of recognition 
of the 1-42 aminoacid Aβ monomers and the optimal binding yield of the capture 
antibody on the coated silicon surface. Finally, incubation conditions were optimised 
to achieve the lowest Aβ(1-42) limit of detection (LOD) using an artiﬁcial CSF sample 
[Gagni et al., 2013]. In the same conditions the LOD for Aβ(1-40) was evaluated. 
Moreover, this tool has been applied to detect both the Aβ peptides in real human CSF 
samples. 
 
 
6.1 - MATERIALS AND METHODS 
6.1.1 - Materials 
Phosphate buffered saline (PBS), Trizma base (Tris) , HCl, ethanolamine, NaCl, KCl, 
CaCl2,MgCl2 ° 6H2O, Sodium bicarbonate, Sodium phosphate, Glucose, Human serum 
albumin (HSA), Tween 20, ammonium sulphate, N,N-dimethylacrylamide (DMA), 3-
(trimethoxysilyl)propylmethacrylate (MAPS), ammonium persulfate (APS), 
tetramethylethylenediamine (TEMED) and N,N’-methylenebisacrylamide (Bis) were 
purchased from Sigma-Aldrich (St. Louis, MO, USA).  
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Amyloid-β (1–42) and Amyloid-β (1-40) were bought from Anaspec (Fremont, CA , 
USA). Amyloid-β (1–39) was a kind gift from Prof. Annalise E. Barron (Stanford 
University, CA , USA).  
Mouse monoclonal antibodies to full-length Amyloid-β (clone 12F4), to amino acids 1–
16 (clone 6E1) and to amino acids 17–24 (clone 4G8) were purchased from Covance 
(Princeton, NJ, USA). Mouse monoclonal antibodies to the Amyloid-β A4 N-terminus 
(clone 1E8 and clone 11H3) and C-terminus (clone 8G7) were bought from Nanotools 
(Teningen, Germany). Goat polyclonal antibody to the Amyloid-β C-terminus (clone D-
17) was bought from Santa Cruz Biotechnology (Santa Cruz, CA , USA). Mouse 
monoclonal antibodies to Amyloid-β amino acids 1–42 (clone G2-13 and clone W0-2) 
were purchased from Millipore (Temecula, CA , USA). Rabbit polyclonal Amyloid-β anti-
oligomer antibody (clone A11) was bought from Invitrogen (Frederick , MD, USA). 
Mouse monoclonal antibody to the Aβ(1-40) carboxy terminus clone G2-10 was bought 
from Millipore (Temecula, CA , USA), while the clones 29-6 and 11A50-B10 against the 
same epitope were purchaised from Covance (Princeton, NJ, USA). 
Goat anti-Rabbit IgG, Cyanine 3-labeled streptavidin (SA-Cy3) and Cyanine 3-labeled 
Rabbit anti-Mouse IgG were obtained from Jackson Immunoresearch (West Grove, PA , 
USA).  
Real human samples of CSF were kindly provided by Prof. Markus Otto (University of 
Ulm, Germany) and by Dr. Roberta Ghidoni (IRCCS Fatebenefratelli of Brescia, Italy). 
Silicon oxide chips with a 100 nm thermal oxide layer were bought from Silicon Valley 
Microelectronics (Santa Clara, CA , USA) and IRIS chips with a 500 nm thermal oxide 
layer were a kind gift from Prof. Selim M. Unlu from Boston University, MA (USA). 
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6.1.2 - Amyloid-β solutions in artificial cerebrospinal fluid (ACSF) 
The Aβ(1–42) and Aβ(1–39) lyophilised peptides were dissolved in 40 µL of 1M 
Ammonia, sonicated for one minute, diluted with 20mM sodium phosphate buffer (pH 
7.4) to a ﬁnal concentration of 200 mM (1 mg/mL) and divided into small aliquots, 
stored at -80° C. 
Artificial cerebrospinal fluid (ACSF) was used in microarray assays in order to mimic 
physiologic conditions. ACSF is an acqueous buffer at pH 7.3 containing 120 mM NaCl, 
25 mM NaHCO3, 2.5 mM KCl, 1 mM NaH2PO4, 2.5 mM CaCl2, 1 mM MgCl2 ° 6 H2O and 
20 mM glucose. Human serum albumin (HSA) was added before use at a mean 
concentration of 0.4 mg/mL. 
 
6.1.3 - Coating of microarray slides with poly(DMA-NAS-MAPS) 
Poly(DMA-NAS-MAPS)-coated silicon microarrays were fabricated according to the 
protocol described in paragraph 5.1.2. Brieﬂy, silicon chips were immersed in a 
poly(DMA-NAS-MAPS) solution (1% w/v in 0.9 M (NH4)2SO4) for 30 min. The chips were 
then rinsed with water, dried under nitrogen and cured for 15 min under vacuum at 
80° C [Cretich et al., 2009b]. 
 
6.1.4 - Aggregation status of Aβ(1-42) and Aβ(1-39) by circular dichroism spectroscopy 
Far-UV circular dichroism (CD) spectra were recorded with a Jasco 600 spectro-
polarimeter over the 190–250 nm range at 25° C, using an optical path of 0.1 cm. The 
peptide concentration used was 50 mM. The spectrum of the blank sample was 
subtracted from all sample spectra, which were then baseline corrected and smoothed 
using Spectra Analysis JASCO software. Aβ(1–42) and Aβ(1–39) frozen stocks were 
thawed and diluted in ACSF (HSA-free) to a ﬁnal concentration of 50 mM. HSA was 
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intentionally removed from the ACSF as it would prevent Aβ(1–42) detection [Gagni et 
al., 2013]. 
 
6.1.5 - Microarray experiments with Aβ(1-42) 
For the label-free IRIS imaging, antibodies against Aβ(1–42) (mouse monoclonal 
antibodies from Covance: clones 4G8, 12F4 and Biotin-labeled 6E10; mouse 
monoclonal antibodies from Nanotools: clones 1E8, 11H3 and 8G7; goat polyclonal 
antibody from Santa Cruz: clone D-17; mouse monoclonal antibodies from Millipore: 
clone G2-13 and W0-2; rabbit polyclonal anti-oligomer antibody from Invitrogen: clone 
A11) were patterned on IRIS chips using a SciFlexArrayer S5 spotter from Scienion 
(Berlin, Germany). Each protein was spotted in PBS in one array corresponding to one 
area on the chip. In the experimental conditions used, the volume of the spotted drops 
was 400 pL. Printed chips were placed in a humid chamber and incubated overnight at 
room temperature. The chips were then blocked with 50 mM ethanolamine solution in 
1 M TRIS/HCl pH 9 for 1 h, washed with water and dried under a stream of nitrogen. 
IRIS images were acquired and ﬁtted with Zoiray Acquire software. For each protein, 
signals from 35 replicate spots were averaged [Gagni et al., 2013]. 
For the ﬂuorescence detection of Aβ(1–42) and Aβ(1–39), capture antibodies against 
Amyloid-β (clone D-17 from Santa Cruz; clone 11H3 and 8G7 from Nanotools; clone 
12F4 and 4G8 from Covance) and Cyanine 3-labeled with streptavidin (reference) were 
patterned on silicon chips using a SciFlexArrayer S5 spotter from Scienion (Berlin, 
Germany). The capture antibodies were spotted in PBS in 12 replicates on each chip. 
The volume of the spotted drops was 400 pL. Printed chips were placed in a humid 
chamber and incubated overnight at room temperature. The chips were then blocked 
with 50 mM ethanolamine solution in 1 M TRIS/HCl pH 9 for 1 h, washed with water 
and dried under a stream of nitrogen. The chips were then incubated with Aβ(1–42) or 
Aβ(1–39) diluted in ACSF. Chips were then washed with washing buffer (0.05 M 
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Tris/HCl pH 9, 0.25 M NaCl, 0.05% v/v Tween-20) for 10 min with stirring, rinsed with 
water, and incubated with the biotin-labeled secondary antibody (mouse monoclonal 
antibody to Amyloid-β amino acids 1–16, clone 6E10, from Covance) at 1 mg/mL in PBS 
for 1 h. Chips were then washed with PBS and water for 10 min each and then 
incubated for 1 h with Cy3-streptavidin (Jackson Immunoresearch) at 2 mg/mL in PBS. 
Chips were washed again with PBS and water for 10 min each. Fluorescence was 
measured by a ProScanArray scanner (PerkinElmer, Boston, MA), and silicon chips 
were analysed using 80% or 90 % Photomultiplier (PMT) gain and laser power. The 
ﬂuorescence intensities of 12 replicate spots were averaged. 
For detection limit experiments, 9 chips were incubated for 2 h in either dynamic or 
static conditions with Amyloid-β at 100, 50, 20, 5, 2, 1, 0.5, 0.1 and 0 ng/mL in ACSF. 
For overnight experiments, chips were incubated for 18 h under static conditions, 
washed with washing buffer for 10 min with stirring, rinsed with water, and incubated 
with the Biotin-labeled secondary antibody (mouse monoclonal antibody clone 6E10, 
from Covance) at 1 mg/ml in PBS for 1 h. The chips were washed with PBS and water 
for 10 min each and then incubated for 1 h with Cyanine 3 labeled with streptavidin 
(Jackson Immunoresearch) at 2 mg/mL in PBS. Chips were washed again with PBS and 
water (10 min each). Fluorescence intensities of 36 replicate spots were averaged. 
Calibration curves (dose–response curves) were generated using a three-parameter 
equation in the OriginLab software. The detection limit (LOD) was deﬁned as the 
analyte concentration corresponding to a signal of three times the standard deviation 
(3σ) above the background signal as calculated from the linear range of the calibration 
curves [Gagni et al., 2013]. 
Moreover, the capture antibodies clone D-17 from Santa Cruz and clone 12F4 from 
Covance and Cy3 labeled with streptavidin (as reference) were patterned on silicon 
chips according to the same spotting protocol previously described. Printed chips were 
placed in a humid chamber and incubated overnight at room temperature and then  
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blocked with 50 mM ethanolamine solution in 1 M TRIS/HCl pH 9 for 1 h, washed with 
water and dried under a stream of nitrogen. The chips were incubated with real 
human samples of CSF, kindly provided by Prof. Marcus Otto (University of Ulm, 
Germany), in both static and dynamic conditions, each for 2 h or overnight. 
Fluorescence detection was performed using the Cov-6E10 biotin-labeled antibody 
coupled with Cy3-labeled streptavidin, and then resulting signals were measured by a 
ProScanArray scanner (PerkinElmer, Boston, MA), and silicon chips were analysed 
using 80% or 90 % Photomultiplier (PMT) gain and laser power. The signal-to-noise 
ratios of 9 replicate spots were eavaluated. 
 
6.1.6 - Detection of Aβ(1-40) in ACSF 
For the ﬂuorescence detection of Aβ(1–40), capture antibodies against both Amyloid-β 
peptides (1-40) and (1-42) (as control of specific binding) together with SA-Cy3 (as 
reference) were patterned on poly(DMA-NAS-MAPS)-coated silicon chips using a 
SciFlexArrayer S5 spotter from Scienion (Berlin, Germany). The capture antibodies 
were spotted in PBS in 18 replicates on each chip. The volume of the spotted drops 
was 400 pL. Printed chips were placed in a humid chamber and incubated overnight at 
room temperature. The chips were then blocked with 50 mM ethanolamine solution in 
1 M TRIS/HCl pH 9 for 1 h, washed with water and dried under a stream of nitrogen. 
The chips were then incubated for 2 hours either in static or dynamic conditions, with 
50 ng/mL Aβ(1–40) or Aβ(1–42) diluted in ACSF otherwise with blank samples. Chips 
were then washed with washing buffer for 10 min with stirring, rinsed with water, and 
incubated with the biotin-labeled secondary antibody (mouse monoclonal antibody to 
Amyloid-β amino acids 1–16, clone 6E10, from Covance) at 1 mg/mL in PBS for 1 h. 
Chips were then washed with PBS and water for 10 min each and then incubated for 1 
h with Cy3-streptavidin at 2 mg/mL in PBS. Chips were washed again with PBS and 
water for 10 min each. Fluorescence was measured by a ProScanArray scanner 
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(PerkinElmer, Boston, MA), and silicon chips were analysed using 90% Photomultiplier 
(PMT) gain and laser power. The ﬂuorescence intensities of 18 replicate spots were 
averaged. 
According to this protocol, several concentration of Aβ(1-40) were tested with both 
static and dynamic conditions in order to define calibration curves from which to 
extrapolate limits of detection, according to the same statistics applied for Aβ(1-42) 
calculations. 
 
6.1.7 - Contemporary detection of Aβ(1-40) and Aβ(1-42) in human CSF 
In order to contemporary detect both peptides Aβ(1–40) and Aβ(1–42), two capture 
antibodies against their C-termini were patterned on poly(DMA-NAS-MAPS)-coated 
silicon chips. Thus, antibodies from Covance, repsectively Cov11A50-B10 and Cov-
12F4, and Cy3-labeled streptavidin (as reference) were spotted on four chips according 
to the same printing protocol described above. Chips were then placed in a humid 
chamber and incubated overnight at room temperature. Subsequently they were 
blocked with 50 mM ethanolamine solution in 1 M TRIS/HCl pH 9 for 1 h, washed with 
water and dried under a stream of nitrogen. Each chip was then incubated for 2 hours 
in static conditions with human CSF samples, kindly provided by Dr. Ghidoni, from 
IRCSS Fatebenefratelli (Brescia, Italy). Chips were then washed with washing buffer for 
10 min with stirring, rinsed with water, and incubated with the biotin-labeled 
secondary antibody (mouse monoclonal antibody to Amyloid-β amino acids 1–16, 
clone 6E10, from Covance) at 1 mg/mL in PBS for 1 h. Chips were washed with PBS and 
water for 10 min each and then incubated for 1 h with Cy3-streptavidin at 2 mg/mL in 
PBS. Chips were washed again with PBS and water for 10 min each. Fluorescence was 
measured by a ProScanArray scanner (PerkinElmer, Boston, MA), and silicon chips 
were analysed using 90% Photomultiplier (PMT) gain and laser power.  
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6.2 - RESULTS AND DISCUSSION 
6.2.1 - Control of Aβ(1-42) and Aβ(1-39) aggregation status 
As mentioned in the introductive session of the present chapter, several isoforms of 
the Amyloid-β peptide exist, which mainly differ at the carboxy terminus. Aβ(1-42) is a 
difﬁcult peptide to work with, in the sense that its aggregation properties are highly 
sensitive to sequence, purity and preparation conditions.In vitro, the longer form 
Aβ(1–42) aggregates faster than the short forms Aβ(1–40) and Aβ(1–39) [Seilheimer et 
al. 1997]. Indeed, this high propensity to form oligomers decreases Aβ(1–42) detection 
efﬁciency, making accurate evaluation of the detection limit very difﬁcult. The actual 
monomeric peptide concentrations in the commercial samples are largely unknown 
[Ammar et al. 2013]. In this work, the aggregation status of Aβ(1-42) standards used 
was assessed by circular dichroism (CD) spectroscopy. In particular, solubility, storage 
conditions and stability of the aggregates during the assay of the longer  form Aβ(1–
42) were compared with that of the shorter form Aβ(1–39). The CD spectra suggest 
that Aβ(1–42) in ACSF (Figure 6.3) maintains a stable structure for at least 2 h, which is 
the time used for microarray incubations in most experiments performed in this study. 
After 24 hours incubations in ACSF, a cloudy precipitate, most likely composed of 
insoluble oligomers, was observed. This is consistent with a random coil structure, as 
determined by CD. In contrast, the shorter form Aβ(1–39) did not show any 
conformational change (Figure 6.4), corroborating the greater stability of this peptide 
compared with Aβ(1–42) [Gagni et al., 2013]. 
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Figure 6.3 - CD specta of Aβ(1-42) in ACSF at different times. A fresh Aβ(1-
42) sample shows a random coil structure (t=0h) which rapidly evolves 
into a β-sheet conformation within 2 h. 
 
 
Figure 6.4 - CD spectra of Aβ(1-39) in ACSF at different times. The shorter 
peptide Aβ(1-39) does not show any aggregation propensity: the random 
coil structure of the fresh sample (t=0h) is maintained over 24 h, thus 
suggesting the greater stability of this peptide. 
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6.2.2 - Matched pair antibody selection for Aβ(1-42) in ACSF 
The binding yield and spot morphology chips of several commercial antibodies against 
different epitopes on the Aβ(1-42) peptide immobilized on poly(DMA-NAS-MAPS)-
coated silicon were evaluated by label-free IRIS. Table 6.3T reports for each antibody 
evaluated in this study: epitope specificity, concentration of the spotted solution and 
amount of antibody bound to the surface (ng/mm2). A typical image of the spot 
morphology is also shown. 
 
Table 6.3T - Deteails for antibodies used in this study. The epitope specificity, spotted solution 
concentration and image showing the typical spot morphology and the antibody binding yeld 
on the surface (ng/mm2) when analysed by LowMag-IRIS are presented. 
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Among the ten antibodies analysed, six were selected for subsequent functional tests: 
SC-D17, NT-11H3, NT-8G7, Cov-4G8, Cov-12F4 and Cov-6E10. Both antibodies from 
Millipore, clones W0-2 and G2-13, were kept out due to their low binding on the 
support (0.56 and 0.68 ng/mm2, respectively). Similarly, the NT1E8 antibody was also 
left out for its poor spot morphology while A11 for being speciﬁc for soluble oligomers. 
The antibodies SC-D17, NT-11H3, NT-8G7, Cov-4G8 and Cov12F4 were tested further 
as Aβ(1-42) and Aβ(1-39) capturing antibodies, using the biotin-labeled Cov-6E10 for 
the detection, followed by incubation with Cy3 labeled streptavidin (SA-Cy3). The assay 
scheme is outlined in Figure 6.5. This experiment aimed to select the best capture 
antibody in terms of signal intensity and speciﬁcity for the Aβ(1-42) peptide. 
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Figure 6.5 – Assay scheme for the selection of matched antibody pair for Aβ(1-42) in ACSF. The 
antibodies SC-D17 (pink), NT-11H3 (blu), NT-8G7 (brown), Cov-4G8 (orange) and Cov12F4 
(green) were arrayed on the same silicon chip (step a) and tested further as Aβ(1-42) and Aβ(1-
39) capturing antibodies (step b). The biotin-labeled Cov-6E10 (red) uas used for the detection, 
followed by incubation with Cy3 labeled streptavidin (SA-Cy3) (step c).  
 
 
Fluorescence images from the analysis of 100 ng/mL of Aβ(1-42), 100 ng/mL Aβ(1-39) 
and a blank sample, with a similar ﬂuorescence value at 80% laser and PMT gain, are 
shown in Figure 6.6. The antibodies SC-D17 and Cov-12F4 resulted in higher signal 
intensity and speciﬁcity for Aβ(1-42) as indicated by the absence of any ﬂuorescence 
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for Aβ(1-39). On the contrary, antibodies NT-11H3 and NT-8G7 did not provide any 
signal either for Aβ(1-42) and Aβ(1-39). Capture antibody Cov-4G8 gave intense signals 
when incubating with both Aβ(1-42) and Aβ(1-39), thus lacking in specificity for the 
interested peptide. 
 
 
 
Figure 6.6 - Fluorescence images and intensities values (mean and SD using 80% 
laser power and PMTgain) for the detection of Aβ(1-42), Aβ(1-39) and a blank 
using SC-D17, NT-11H3, NT-8G7, Cov-4G8 and Cov-12F4 antibodies as capture 
reagents and biotinilated Cov-6E10 as the detection antibody. In addition to 
optimal speciﬁcity for Aβ(1–42), the antibody matched pair SC-D17/Cov-6E10 and 
Cov12F4/Cov-6E10 resulted in absence of ﬂuorescence for the blank samples and 
were therefore chosen as the optimal matched reagents for Aβ(1-42) detection in 
this study. 
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Although sandwich immunoassay is the gold standard for protein proﬁling, antibody 
cross-reactivity is often observed in this method. This effect produces background 
noise, which affects sensitivity and causes false positive results [Ellington et al. 2010]. 
In addition to the intensity of ﬂuorescence, when detecting the target analyte, it is of 
high importance to check for signal absence from the blank sample at high laser power 
and PMT gain. In fact, the sensitivity of microarray-based immunoassays depends on 
the elimination or at least the minimisation of cross-reactivity between the capture 
and detection antibodies. In addition to being most speciﬁc for Aβ(1–42), these two 
matched antibody pairs (SC-D17/Cov-6E10 and Cov-12F4/Cov-6E10) resulted in the 
absence of ﬂuorescence for the blank samples and, therefore, were chosen as the 
optimal matched reagents for Aβ(1-42) detection in this study [Gagni et al., 2013]. 
 
6.2.3 - Limits of detection for Aβ(1-42) in ACSF 
The antibodies SC-D17 and Cov-12F4 were immobilised on poly(DMA-NAS-MAPS) 
coated silicon slides as previously described. The chips were incubated with several 
concentrations of Aβ(1-42) dissolved in artiﬁcial cerebrospinal ﬂuid (ACSF), in order to 
mimic the composition of endogenous CSF, in static (using a cover slip) and dynamic (in 
a petri dish on a horizontal shaker at 50 rpm) conditions, followed by incubation with 
Cov-6E10 biotin-labeled detection antibody and Cy3-labeled streptavidin (SA-Cy3). 
Fuorescence intensities obtained upon incubation with Aβ(1-42) in the ng/mL range 
provided data that were fitted to the three-parameter logistic equation in order to 
determin the calibration curves reported in Figure 6.7. Curves were obtained with both 
capture antibodies, respectively Cov-12F4 on the left and SC-D17 on the right column, 
for the three different incubation protocols: 2 h dynamic (first line), 2 h static (second 
line) and overnight static conditions (third line). 
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Figure 6.7 - Calibration curves obtained for all tested conditions. The left panel shows the 
calibration obtained curves using COV-12F4 as the capture antibody for Aβ(1-42) detection 
when incubation was performed under dynamic conditions for 2 h (a), static conditions for 
2 h (b) and static conditions overnight (c). The right panel shows calibration curves obtained 
using SC-D17 as the capture antibody for Aβ(1-42) detection when incubation was 
performed under dynamic conditions for 2 h (d), static conditions for 2 h (e) and static 
conditions overnight (f). 
 
 
Figure 6.8 shows the ﬁtted dose–response curves obtained using a 2 h dynamic 
incubation with matched antibody pairs Cov-12F4/Cov-6E10 at 90% laser power and 
PMT gain. Panel b focuses on the linear range of the curve, which yielded a limit of 
detection of 73.07 pg/mL. 
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Figure 6.8- a) Calibration curvefor Aβ(1-42) detection in ACSF with 
Cov-12F4 as the capture antibody and Cov-6E10 as the detection 
antibody and 90% laser power and PMT gain. Aβ(1-42) was incubated 
under dynamic conditions for 2h. b) Close-up of the liner range of the 
curve, which yielded a LOD of 73.07 pg/mL. 
 
 
Limits of detection (LODs) were extrapolated from the average ﬂuorescent value of the 
blank samples plus three standard deviations (3s) using the linear range of the 
calibration curves [Wild, 1998]. Among the multiple factors that affect detection 
sensitivity in ﬂuorescent microarrays, optimal assay design to compensate for kinetic 
limitations [Kusnezow et al., 2006] is of high importance. 
Table 6.4T shows that the LODs obtained using either 2 h of dynamic and static 
incubation or overnight static incubation with SC-D17 as the capture antibody are all in 
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the ng/mL range. With Cov-12F4 as the capture antibody, the LODs were in the pg/mL 
range (Table 6.5T) [Gagni et al., 2013]. 
 
 
 
Table 6.4T – LODs for Aβ42 using SC-D17/Cov-6E10 matched antibody pair. 
Incubation conditions: Static, 2h Dynamic, 2h Static, overnight 
Aβ(1-42) LOD (ng/mL) 6.76 1.13 7.76 
 
 
Table 6.5T - LODs for Aβ42 using Cov-12F4/Cov-6E10 matched antibody pair 
Incubation conditions: Static, 2h Dynamic, 2h Static, overnight 
Aβ(1-42) LOD (pg/mL) 148.36 73.07 94.15 
 
 
 
As expected, for both antibodies, incubation under dynamic conditions was more 
sensitive compared with the static one. However, overnight incubation did not provide 
a signiﬁcant improvement in the LODs, probably due to the ongoing aggregation of 
Aβ(1-42) in solution which was previously observed in CD analysis. Although the mouse 
monoclonal antibody Cov-12F4 had a lower binding yield on poly(DMA-NAS-MAPS)-
coated silicon compared with the goat polyclonal antibody SC-D17 (resectively, 1.52 vs. 
2.89 ng/mm2 as reported in Table 6.3T), it allowed detection limits approximately one 
order of magnitude lower in all tested conditions, most likely due to its higher afﬁnity 
towards Aβ(1-42). Figure 6.9 shows the ﬂuorescence results from arrays after 2 h of 
dynamic incubation with 0, 0.1, 0.5, 1, 2, 5, 20, 50 and 100 ng/mL of Aβ(1-42) in ACSF 
using the two tested capture antibodies, SC-D17 and Cov-12F4 [Gagni et al., 2013]. 
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Figure 6.9 - Fluorescence images (at 90% laser power and PMT gain) of Aβ(1-42) detection 
using SC-D17 (upper array) or Cov-12F4 (lower array) as the capture antibody and Cov-
6E10 as the detection antibody. Samples with concentrations ranging from 0 to 100 ng/mL 
were analysed. 
 
 
Cov-12F4 gave a clear ﬂuorescence response even at the lowest concentration tested, 
whereas SC-D17 yielded detectable signals only for concentrations higher than 5 
ng/mL. These data indicate that Cov-12F4 allows to achieve a detection limit one order 
of magnitude lower [Gagni et al., 2013]. 
In summary, the best conditions developed for Aβ(1-42) detection consisted of the use 
of Cov-12F4/Cov-6E10 matched antibody pair and 2 h of dynamic incubation and 
resulted in the unprecedented microarray LOD of Aβ(1-42) in ACSF of 73.07 pg/mL 
[Gagni et al., 2013]. This value is compatible with the use of the proposed assay in 
diagnostics, where controls show a concentration of Aβ(1-42) in CSF of 794 ± 20 pg/mL 
and AD patients show a concentration lower than 500 pg/mL [Humpel, 2011]. 
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6.2.4 - Aβ(1-42) detection in human CSF 
Reagents and protocols developed in this study were tested with real human samples 
of CSF (kindly provided by Prof. Markus Otto, University of Ulm). 
Figure 6.10 shows the typical results for the detection of Aβ(1-42) in CSF using Cov-
12F4/Cov-6E10 matched antibody pair and four different incubation conditions, 
including both static incubation for 2 h or overnight and dynamic incubation for 2 h or 
overnight. In contrast to the use of standard Aβ(1-42) in ACSF, either in static or 
dynamic conditions an overnight incubation resulted in an increased signal to noise 
ratio. This event is most likely because in real human samples, the aggregation 
phenomenon observed in artiﬁcial CSF does not occur or rarely occurs, and a longer 
incubation time allows the analyte to reach the equilibrium. However, a further 
validation of the proposed assay using clinical samples is currently underway in our 
laboratory [Gagni et al., 2013]. 
 
 
 
Figure 6.10 - Representative image of Aβ42 detection in a human CSF sample using 
Cov12F4 as capture antibody and Cov-6E10 as detection antibody. For both static and 
dynamic incubation, a longer incubation time yielded higher signal-to-noise responses. 
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6.2.5 - Detection of Aβ(1-40) in ACSF 
Three antibodies were tested as capture probes against the carboxy terminus of the 
Amyloid-β (1-40) peptide, while the selected Cov-6E10 biotin-labeled antibody was 
used for detection as it recognizes the ammino terminus of the same target.  
Static incubations were performed with 50 ng/mL of Aβ(1-40) in ACSF in comparison 
with the same concentration of Aβ(1-42) and the blank sample. As reported in Figure 
6.11, the capture probes for the Aβ(1-42) isoform (SC-D17 and Cov-12F4 antibodies) 
do not recognize the Aβ(1-40), while a high interaction is provided by the Millipore G2-
10 and the Cov11A50-B10 antibodies, which were selected for further investigation 
concerning their specificity. The best antibody pair is the Millipore G2-10/Cov6E10 as 
the blank sample does not display any fluorescence. The Cov 29-6 slightly interacts 
with the target and thus it was not used further. 
 
 
 
Figure 6.11 – Fluorescence signals (at 90% laser power and PMT gain) from arrays 
incubated with 50 ng/mL Aβ(1-40) in ACSF (left column) or blank sample (right column) 
and detected with biotin-labeled Cov-6E10 antibody, coupled with SA-Cy3. Each line 
corresponds to a different capture antibody, spotted on the surface: two antibodies 
specific for Aβ(1-42) as control of specificity (SC-D17 and Cov-12F4) and three antibodies 
for Aβ(1-40) to be tested (Cov 29-6, Cov11A50-B10 and Millipore G2-10). 
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In order to validate the specificity of Aβ(1-40) detection, the same antibody pairs 
(Millipore G2-10/Cov-6E10 and Cov11A50-B10/Cov-6E10) were incubated in dynamic 
conditions with 50 ng/mL of Aβ(1-42) peptide. As shown in Figure 6.12, no signals 
were detectable on the interested spot. 
 
 
 
Figure 6.12 – Fluorescence signals (at 90% laser power and PMT gain) from 
arrays incubated with 50 ng/mL Aβ(1-42) in ACSF (left column) or blank 
sample (right column) and detected with biotin-labeled Cov-6E10 antibody, 
coupled with SA-Cy3. Each line corresponds to a different capture antibody 
against Aβ(1-40) carboxy terminus: Cov11A50-B10 and Millipore G2-10. 
 
 
By incubating with several concentration of Aβ(1-40) peptide, limits of detection 
(LODs) of this peptide were extrapolated when using both matched antibody pairs: 
Millipore G2-10/Cov-6E10 and Cov11A50-B10/Cov-6E10. The incubation protocols 
were the same performed for the Aβ(1-42) peptide, using both static and dynamic 
incubations. 
As reported in Table 6.6T, the Cov11A50-B10 provided a LOD of 2.05 ng/mL in static 
conditions, but no gain in detection limits was achieved when incubationg in dynamic 
conditions as a value of 2.14 ng/mL was obtained. On the contrary, the capture 
 84 
antibody Millipore G2-10 provided a LOD of 0.35 ng/mL in dynamic incubations, much 
lower than the 2.15 ng/mL value obtained in static ones.  
 
 
Table 6.6T – LODs (ng/mL) for Aβ(1-40) using two selected matched antibody pairs. 
Capture antibody Static, 2h Dynamic, 2h 
Cov11A50-B10 2.05 ng/mL 2.14 ng/mL 
Millipore G2-10 2.15 ng/mL 0.35 ng/mL 
 
 
The possibility to capture the Amyloid peptideS through their carboxy terminus and to 
detect them using a common antibody against the ammino terminus enabled the 
development of a microarray-based immunoassay able to detect at the same time, on 
a single device, both Aβ(1-40) and Aβ(1-42) present in a given sample.The obtained 
results are compatible with the use of the proposed assay in diagnostics, where CSF 
controls show a concentration of about 800 pg/mL for Aβ(1-42) and 7 ng/mL for Aβ(1-
40) [Humpel et al., 2011]. 
 
6.2.6 - Contemporary detection of Aβ(1-40) and Aβ(1-42) in human CSF 
The fluorescence-based microarray immunoassay developed in this thesiswas applied 
to the simultanoeus detection of both Amyloid-β peptides (1-40) and (1-42) on a single 
device in human CSF samples. To reach this goal, two subarrays were patterned on 
each chip, corresponding to the capture antibodies selected for each target analyte: 
Cov11A50-B10 and Cov-12F4, respectively. Four CSF samples were kindly provided by 
Dr. Roberta Ghidoni from IRCSS Fatebenefratelli (Brescia, Italy). Due to the low amount 
of human CSF available, it was not possible to perform dynamic incubations, which 
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require more than 1 mL of sample. Thus, as outlined in Figure 6.13, 20 uL of each 
solution was assayed using static conditions. The two peptides were captured on each 
subarray with antibodies specific for their C-termini, while the detection by Cov-6E10 
biotin-labeled antibody occured through the recognition of the common N-terminus of 
both analytes. 
 
 
 
Figure 6.13 – Assay scheme for the contemporary detection of both Aβ(1-40) and Aβ(1-
42) in human CSF samples on a single device. Two capture antibodies are arrayed on the 
same chip: Cov11A50-B10 was selected as being specific for Aβ(1-40), while Cov-14F4 for 
Aβ(1-42). 20uL of CSF samples were incubated for 2h in static conditions and then 
detected by the common biotin-labeled Cov6E10 antibody, followed by incubation with 
Cy3-labeled streptavidin. 
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The fluorescence signals shown in Figure 6.14, demonstrate the capability of this 
microarray to detect at the same time both analytes in CSF in a specific manner, 
although possible physiological variations of peptides in real samples may occur. 
 
 
 
Figure 6.14 – Fluorescence detection (at 90% laser power and PMT 
gain) from arrays incubated for 2 hours in static conditions with four 
human CSF samples. Per each sample, both Aβ(1-40) (left column) 
and Aβ(1-42) (right column) were detectable. 
 
 
 
6.3 - CONCLUSIONS 
Alzheimer Disease (AD) is a Neurodegenerative disorder, characterized by abnormal 
extracellular accumulation of β-Amyloid peptide in the brains of patients. The 
pathological isoform Aβ(1-42) agregates order of magnitudesfaster than Aβ(1-40) or 
Aβ(1-39) [Silheimer et al., 1997]. However the analysis of the sole Aβ(1-42) 
concencentration is not specific enough for the discrimination of AD from other kinds 
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of Dementia in subjects with constitutively high or low levels of total Aβ peptides. 
Thus, it may be better to consider the ratio between Aβ(1-42)/Aβ(1-40) for higher 
reliability [Wiltfang et al., 2007]. Therefore, a method to detect simoultanously both 
analytes in cerebrospinal fluids is needed. Because of their multiplexing capability, low 
sample volume consumption and sample-to-result time, microarrays are ideal tools for 
the identification of individuals with preclinical AD who are still cognitively healthy in 
population-wide screenings. 
In this work, a highly sensitive fluorescence immunoassay that utilizes silicon/silicon 
oxide substrates for the detection of the AD biomarkers Aβ(1-40) and Aβ(1-42) in 
artificial cerebrospinal fluid (ACSF) has been developed [Gagni et al., 2013]. 
In preliminary tests, the commercial peptides Aβ(1-42) and Aβ(1-39) aggregation 
status were assessed by Circular Dicroism, demonstrating the stability of Aβ(1-42) 
structure for at least 2 hours, while Aβ(1-39) does not show any conformational 
changes, even in 24 hours. Thereafter, an optimal antibody matched pair for Aβ(1-42) 
detection was selected with a label and label-free microarray platform, using the 
Interfermometric Reflectance Imaging Sensor (IRIS), to determine binding yield on the 
silicon surface and the spot morphology. The selected antibodies were tested on 
poly(DMA–NAS–MAPS)-coated silicon chips for Cy3-label microarray analysis [Cretich 
et al., 2009b]. Two antibody-matched pairs resulted specific and sensitive for Aβ(1-42).   
To selectively detect Aβ(1-40), different capture antibodies were selected based on 
their specificity for the C-terminus of the peptide. In this way, both Aβ(1-42) and Aβ(1-
40) were simultaneously detected on a multiplexed fluorescence microarray using the 
same biotin-labeled antibody against the common N-terminus sequence of the 
peptides and the respective LODs were extrapolated. The best condition developed for 
Aβ(1-42) detection in ACSF requires 2 hours of dynamic incubation, resulting in a LOD 
of 73 pg/mL [Gagni et al., 2013]. In the same conditions the LOD for Aβ(1-40) was 350 
pg/mL. The obtained results are compatible for the use of the proposed assay in 
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diagnostics, where CSF controls show a concentration of about 800 pg/mL for Aβ42 
and 7 ng/mL for Aβ40 [Humpel, 2011]. As a proof of concept, thefluorescence-based 
tool was applied to simultaneouslydetect on single chipthese two biomarkers in real 
human CSF samples [Gagni et al., 2013]. 
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Chapter 7 - Direct and Indirect Detection of intact 
Exosomes on dual Fluorescence-based and Label-free 
Microarray Platform 
 
 
 
Dual fluorescence and label-free microarray platform has been further extended to the 
detection of extracellular vesicles, such as exosomes, through surface antigen-
antibodies recognition. 
Exosomes and microvesicles (MVs) belong to the bigger family of extracellular vesicles 
(EVs) as they both are submicron-sized spheric containers made of phospholipidic 
bilayer membrane, released by any kind of cells and characterized by an aqueous 
cargo-containing core. Although structurally similar, they differ in cellular origin, lipid 
composition, and size [Kastelowitz et al., 2014]. In general, MVs are big particles (100-
1000 nm of diameter), that bear by outward budding and fission of the plasma 
membrane [Al-Nedawi et al., 2009]. Their surface composition is similar to that of the 
cell membrane but lacks the asymmetric distribution of lipids normally seen across the 
two leaflets of the plasma membrane [Scott et al., 1984; Hugel, 2005]. On the contrary, 
exosomes are smaller vesicles, defined on the base of size (40–100 nm) and density 
(1.12-1.19 g/ml). They originate intracellularly by inward budding of the limiting 
membrane of endocytic compartments, leading to vesicle-containing endosomes, 
called multivesicular bodies (MVBs). MVBs eventually fuse with the plasma membrane, 
thus releasing their internal vesicles (i.e., exosomes) into the extracellular medium 
[Théry et al., 2006] through an exocytosis event. Exosomes appear to have a similar 
lipid composition between the two membrane leaﬂets, consistent with the presence of 
a phospholipid-scramblase [Record et al., 2011]. 
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The physiological function of exosomes still remains a matter of debate. Two secretion 
mechanism routes have been described: secretion of exosomes can be constitutive or 
inducible, depending on the cell type and on the activation state of the cell [Théry et 
al., 2009]. In the first way, exosomes secretion is a function per se as vesicles are 
routed through an anterograde pathway from the Trans Golgi Network (TGN) by an 
ubiquitary constitutive pathway that does not require any speciﬁc stimulus or any 
transit via MVBs, and thus they are secreted into the extracellular medium [Record et 
al., 2011]. For example, exosome secretion by reticulocytes allows the elimination of 
proteins such as transferrin receptor or integrins, which are useless in differentiated 
red blood cells [Pan et al., 1985; Vidal et al., 1997]. Differently, basing on a regulated 
mechanism, the second secretion route of exosome release takes advantage from 
MVBs pathway. Depending on the cell type and its activation state many cellular 
stimuli (e.g., calcium-dependent release [Savina et al., 2003], cellular depolarization 
induced by K+ [Record et al., 2011], receptor-mediated release [Qu et al., 2009]) can 
induce MVBs fusion with plasma membrane. However, irrespective to the stimulus, 
this kind of exosome production results involved in intercellular communication, 
allowing exchange of proteins and lipids between the exosome-producing cell and the 
target one [Wolfers et al., 2001; Andre et al., 2002; Théry et al., 2002]. 
In addition to a number of proteins being involved in intercellular signalling, exosomes 
have been found to exhibit a specific content of proteins, lipids and transported micro 
as well as messenger RNAs [Valadi et al., 2007]. As they contain speciﬁc signatures 
from producing-cells, analyses of exosomes may be used for diagnostic purposes, e.g. 
for melanoma [Logozzi et al., 2009] or ovarian cancer diagnosis [Taylor et al., 2008]. 
Universal markers commonly used to identify exosomes include transmembrane 
proteins (like tetraspanins CD9, CD63, CD81, and CD82), major histocompatibility 
complexes (MHC, class-I and -II) and cytosolic proteins (like heat shock proteins, Hsp70 
and Hsp90) [Heijnen et al., 1999; Caby et al., 2005; Lee et al., 2011]. Exosomes protein 
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composition analyses have revealed both an ubiquitary and a cell type-speciﬁc protein 
composition. 
As reported in Figure 7.1, Record and colleagues listed many types of molecules 
tipically found on exosomes [Record et al., 2011]: 
- antigen-presentation (MHC-I, MHC-II) and co-presentation molecules (CD86), 
- cell adhesion (Integrins, MFGE8, etc.), 
- cell structure and motility (actins, myosin, tubulin, etc.), 
- Heat shock proteins and chaperones (Hsp70, Hsp90, Hsc70), 
- metabolic enzymes (β-enolase, fatty acid synthase, glyceraldehyde-3-
phosphate dehydrogenase, peroxidases, pyruvate kinase), 
- proteins referring to exosomes or MVBs biogenesis (e.g. Tsg101, lyso-bis-
phosphatidic acid,  Alix), 
- lysosomal markers (LAMP-1/2), 
- signalling proteins (kinases 143-3, GTPase Hras, RhoA, RAP1B, Guanine 
nucleotide-binding protein subunits, Gproteins, etc.), 
- tetraspanins (CD9, CD63, CD81, CD82), 
- proteins involved in transcription and protein synthesis (histones, ribosomal 
proteins, ubiquitin, etc.), 
- proteins involved in trafﬁcking and membrane fusion (Annexins, Rab protein 
family, ARF). 
However, the functional signiﬁcance of certain proteins is not completely understood. 
It is worth noting that markers commonly used to characterize a composition of 
exosomes may have varying distribution between cell types. For instance, the 
Transferring Receptor (TfR) is absent in exosomes derived from B-cells whereas it is 
present in erythrocyte derived exosomes [Record et al., 2011]. 
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Figure 7.1 - Main typical proteins and lipids present in exosomes. About a 
hundred fold enrichment of tetraspanins (CD9, CD63, CD81, CD82) in exosomes 
comparatively to parent cells is a hallmark of exosomes. Heat shock proteins 
(Hsp90, Hsp70, Hsc70) also are enriched. Activation of phospholipases by GTPases 
(Rab, Rap, ran, RhoA, Arf) and their regulation by aldolase, casein kinase II and 
Hsp/Hsc70 has been reported in literature. The major phospholipids are present 
in exosomes but in distinct proportions as compared to parent cells. The speciﬁc 
MVB lyso-lipid LBPA (BMP) is also found in exosomes [Record et al., 2011]. 
 
 
In this third study, exosomes have been investigated for their role as biomarkers or 
carriers of biomarkers for Neurodegenerative Disorders (NDs). In fact, many cells of 
the nervous system have been shown to release extra-cellular vesicles (EVs), 
implicating their active roles in growth, function, and pathologies of this system. 
Exosomes and microvesicles are capable of transferring DNAs, mRNAs, microRNAs, 
non-coding RNAs, proteins and lipids among cells without direct cell-to-cell contact 
[Fauré et al., 2006]. Moreover, they have recently been proposed to participate in 
myelin formation as well as in neurite outgrowth and neuronal survival [Wang et al., 
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2011]. For these reasons, exosomes from cerebrospinal fluid (CSF) can be considered 
as carriers of biomarkers for neurological disorders [Lachenal et al., 2011]. Exosomes 
are reported to be involved in pathological pathways, such as tumor pathogenesis or 
transmission of viruses, prions and Amyloid-β peptide precipitation in AD [Wolfers et 
al., 2001; Rajendran et al., 2006]. 
In particular, the finding that proteins and peptides associated with AD (i.e. APP -
Amyloid Precursor Protein-, APP C-terminal fragments, APP intracellular domain, 
Amyloid-beta, tau, presenilins) are released in association with exosomes has shed 
light on previously unidentified pathways in the processing of APP and provided 
potential explanation for extracellular amyloid deposition in the brain [Sharples et al., 
2008; Vingtdeux et al., 2007; Ghidoni et al., 2011; Saman et al., 2012; An et al., 2013; 
Saman et al., 2014]. In support to this hypothesis, other exosomal proteins (such as alix 
and flotillin) have been found to accumulate in the plaques of AD brains. 
However it is still a matter of debate if in some pathologies (such as NDs) differences in 
exosome pathways lead to a different content of proteins or to variations in quantity 
of vesicle production, respectively making exosomes carriers of biomarkers or 
biomarkers themselves. For this reason an hot topic of recent researches focused on 
the isolation, detection and characterization of exosomes from different sources in 
order to discover any correlation between their production and content with the 
interested pathology. 
Any cell of animal beings can be an exosome-producing cell, both in vivo and in vitro. 
For example, exosomes have been isolated from different body fluids, such as blood, 
urine, saliva, amniotic fluid, CSF, bile, broncho-alveolar lavage and tumor 
ascites,through a simple collection by the usual means [Théry et al., 2006]. Similarly 
exosomes have also been found in many cell culture supernatants with an average 
level of production of about 0.1 µg/106 cells as a rough general estimate [Théry et al., 
2006]. However, irrespective to their source, the puriﬁcation of exosomes from cell 
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culture supernatants or other biological ﬂuids is not trivial and follows the same 
principle. In particular, when dealing with cell lines, in order to avoid contamination by 
exosomes from serum present in the culture medium, it becomes necessary to grow 
cells in serum-free conditions, to ensure that all vesicles present in the supernatant 
derive from cellular production [Théry et al., 2006]. In order to purify and concentrate 
vesicles from collected samples, the original and most widespread protocol involves 
several centrifugation and ultracentrifugation steps [Raposo et al.,1996]. Nevertheless, 
purification of vesicles from body fluids is usually less efficient due to the high 
complexity of the matrix and the viscosity of the samples themselves. For these 
reasons, it is recommended to dilute them and to increase the speed and lengths of 
centrifugations [Caby et al., 2005]. An alternative new method for purifying exosomes 
is by ultraﬁltration instead of ultracentrifugation, employing cartridges and pumps in a 
way useful when dealing with large volumes (>1 L) of conditioned medium, but it is not 
the easiest option for laboratory applications [Théry et al., 2006]. However, Lamparski 
and colleagues have compared the two preparation methods for the same dendritic 
cell supernatants side by side, using biochemical, morphological, and functional assays 
for exosomes, founding no signiﬁcant differences [Lamparski et al., 2002]. 
The general flowchart of exosome puriﬁcation by ultracentrifugation is depicted in 
Figure 7.2. The ﬁrst steps are designed to eliminate large dead cells and large cell 
debris by successive centrifugations at increasing times and speeds. The first pellet 
contains cellular debris, the second is enriched in MVBs, while only through the third 
centrifugation, ectosomes and exosomes can be separated. Ectosomes are slightly 
bigger vesicles, released from cells upon plasma membrane shedding and bearing 
distinct protein markers, such as CD41 or CD45 [Record et al. 2011]. In order to purify 
exosomes, at each of these centrifugation steps the pellet is thrown away and the 
supernatant is used for the following steps. The ﬁnal supernatant is then 
ultracentrifuged at 110000 × g to pellet the small vesicles that correspond to exosomes 
 95 
(Pellet #4, often indicated as P4). This pellet is then resuspended in an appropriate 
volume of PBS. This preparation is usually stored at 4° C and tests should be set up in 
the immediate following days. Sokolovaa and colleagues characterized exosomes by 
scanning electron microscopy (SEM), dynamic light scattering (DLS) and nanoparticle 
tracking analysis (NTA), measuring a diameter around 110 nm and observing that 
multiple ultracentrifugations do not affect the exosome size [Sokolovaa et al., 2011]. 
Although centrifugation protocols reasonably provide pure exosomes, for some 
applications it may be advisable to include an extra puriﬁcation step using a sucrose 
cushion or by immunoisolation. This further step eliminates more contaminants, such 
as proteins non speciﬁcally associated with exosomes, or large protein aggregates, 
which are sedimented by centrifugation but do not ﬂoat on a sucrose gradient. Hence, 
exosomes from pellet P4, resuspended in PBS, can be loaded on a sucrose gradient 
column (ranging fron 1.125 to 1.186 g/mL) to be fractioned according to their density. 
After 16 hours centrifugation at 200000 x g, each fraction is isolated and furthermore 
centrifuged at 110000 x g for 1 hour. Empty supernatants are discharged while pellets 
are resuspended in an appropriate volume of PBS. These preparations can be stored, 
as well, at 4° C and tests should be set up in the immediate following days. 
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Figure 7.2 - Flowchart of exosomes purification protocol based on differential 
ultracentrifugation. The speed and length of each centrifugation are indicated 
to the left of the arrows. After each of the ﬁrst three centrifugations, pellets 
are discarded, and the supernatant is kept for the next step. In contrast, after 
the final centrifugation, the pellet enriched in exosomes is kept and the empty 
supernatant is discarded. 
 
 
Purified vesicles need to be detected and characterized. Up to now, due to their 
physical properties, it is very difficult to distinguish and characterize exosomes among 
all extra-cellular vesicles (EVs) in biological samples and for these reasons a major 
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ongoing challenge is to establish methods to discriminate between exosomes and 
other types of vesicles [Bobrie et al., 2011]. Since they are too small for direct analysis 
by flow cytometry or other conventional techniques for the analysis of nanoparticles, 
new methods are required to successfully quantify exosomes and to identify their 
cellular origin. Widely applied technologies used for a qualitativedetection of 
exosomes consider them as ultramicroscopic particles. Among all the techniques, the 
most commonly used include electron microscopy (EM), dynamic light scattering (DLS), 
and nanoparticle tracking analysis (NTA).  
EM provides an appropriate evaluation of both the purity of exosome preparations as 
well as their characterization [Théry et al., 2006]. In Figure 7.3, negatively stained 
exosomes reveal cup-shaped membrane vesicles of 50 to 100 nm [Théry et al., 2006]. 
In the extracellular space, highly curved membranes are less common; as most cells 
have higher diameters, nano-sized exosomes represent uniquely curved lipid surfaces 
[Gyorgy et al., 2011]. However it is possible that the morphological appearance of 
exosomes may be inﬂuenced by chemical ﬁxation, used in EM detection protocols 
[Théry et al., 2006]. The “contrasting and embedding” procedure (“positive-negative” 
contrast) was originally developed for ultrathin cryosections, in order to provide a 
reproducible method and to combine both increase in contrast and stabilization of the 
membranes [Théry et al., 2006], as it takes advantage of fixing membranes with 2% or 
4% (w/v) of paraformaldehyde. 
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Figure 7.3 - Electron-microscopic observation of whole-mounted exosomes 
purified from mouse dendritic cells. Arrows indicate exosomes while 
arrowheads point to smaller non-exosomal vesicles. The insert emphasizes 
immunogold labelling of MHC class II molecules, with 10 nm gold particles. 
Scale bar corresponds to 100 nm [Théry et al., 2006].  
 
 
Dynamic light scattering (DLS) is a useful technique which tries to detect exosomes 
based on their low refractive index [Dragovic et al., 2011]. However the actual 
instrumentationsare not able to distinguish between microvesicles (>100 nm) and 
exosomes (<100 nm) in a mixed solution [Lawrie et al., 2009]. On the contrary, 
nanoparticle tracking analysis (NTA) is perhaps the most promising method to detect 
smaller nanoparticles, because it can identify both microvesicles and exosomes and is 
not dependent on their refractive index [Kastelowitz et al., 2014]. However, without a 
fluorescently labeled antibody directed towards a vesicle surface marker or without 
the use of a vesicle isolation method to reduce polydispersity of the sample, there can 
be considerable intra-assay count variability [Dragovic et al., 2011; Oosthuyzen et al., 
2013]. 
Nevertheless, depending on the method used, the reported absolute number of 
extracellular vesicles in a liter of blood can vary by as much as five orders of magnitude 
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[van der Pol et al., 2010]. Moreover, all these techniques share the limit of not being 
applicable in clinical diagnostic tools.  
On the other side, irrespective to a quality control of purified samples, two 
bioanalytical approaches are widely used for a quantitative analysis of exosome 
content:  immunoblotting (e.g., ELISA), which quantifies the amount of a given 
exosomal protein, and the Bradford assay, able to measure the total protein 
concentration in the exosome preparations [Théry et al., 2006]. Both these analysis 
often require the disruption of vesicles and the release of proteins in solution for the 
quantification of the target analyte. 
To overcome the lack of tools suitable for both quantitative and qualitative analysis of 
EVs, this study focused on the development of fluorescence-based and label-free 
microarray platforms able to assess at the same time concentration, size distribution 
and phenotype of intact exosomes. 
Exosomes purified from human fibroblast cell culture were chosen as a standard model 
to set assay conditions, in order to develop a tool available for human plasma samples 
of clinical interest. Prior, direct immunoassay tests were performed to select the best 
antibody against the human tetraspanin CD63 (hCD63), chosen as a typical biomarker 
of exosomes. In the following step, sandwich immunoassays were carried out by 
combining fluorescence-based and label-free detection technologies. In particular, 
conventional IRIS provided quantitative measurements of biomaterial immobilized on 
the surface, while SP-IRIS was useful in defining the size distribution of vesicles in a 
given sample whereas fluorescence was used in their phenotyping. The integration of 
all these type of information, allowed the development of an innovative tool able to 
detect, count and characterize intact exosomes. 
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7.1- MATERIALS AND METHODS 
7.1.1 - Materials 
Phosphate buffered saline (PBS), Trizma base (Tris), HCl, ethanolamine, Bovine Serum 
Albumin (BSA), Tween-20, ammonium sulphate, N,N’-dymethylacrylamide (DMA), 3-
(trimethoxysilyl)propylmethacrilate (MAPS) and paraformaldehyde (PFA)were 
purchased from Sigma-Aldrich (St. Louis, MO, USA). 
Mouse biotin-labeled antibodies against human tetraspanin CD63 (hCD63) were 
purchased from different suppliers: clone 215-030fromAncell (Bayport, MN, USA), 
clone H5C6 from BioLegend (San Diego, CA, USA) andclone MEM-259from ExBio 
(Praha, Czech Republic). Rabbit IgG anti-hCD63, clone EXOEL-CD63A-1, was bought 
from System Biosciences (SBI - Mountain View, CA, USA). Capture IgG against hCD63, 
clone H5C6 was obtained from BioLegend (San Diego, CA, USA). Cy3-labeled 
streptavidin (SA-Cy3), Cy3-labeled Goat anti-Rabbit IgG and Goat anti-Rabbit IgG whole 
molecule were obtained from Jackson Immunoresearch (West Grove, PA, USA). Mouse 
IgG against hCD63 clone H5C6 labeled with 40nm gold nanoparticled (NP-Au) were a 
gift from Prof. Selim M. Unlu from Boston University, MA (USA). 
Silicon chips with a 100 nm thermal oxide layer were bought from Silicon Valley 
Microelectronics (Santa Clara, CA , USA); Single Particle (SP) chips with 100 nm thermal 
oxide layer and IRIS chips with a 500 nm thermal oxide layer were a kind gift from Prof. 
Selim M. Unlu from Boston University, MA (USA). 
Exosomes were purified from human fibroblast cell culture according to the protocol 
reported in the introductive paragraph (Figure 7.2) by Dr. Roberta Ghidoni team from 
IRCSS – Fatebenefratelli (Brescia, Italy). Pellet P4 samples were diluted into a volume 
of 5uL PBS per starting Petri dishes and delivered the same day experiments took 
place. 
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Human plasma samples of clinical interest were a gift from Dr. Roberta Ghidoni (IRCSS 
– Fatebenefratelli, Brescia, Italy), obtained from hospital sample bank, tawed and 
simply centrifuged at 3000g before delivery. 
 
7.1.2- NanoSight measurements 
Suspensions containing vesicles were analysed using a Nano-Sight LM10 instrument 
(NanoSight, Amesbury, UK) by the laboratory of Prof. Prosperi at Bicocca University 
(Milan, Italy). For this analysis, a monochromatic laser beam at 405 nm was applied to 
thedilute suspension of vesicles. A video of 60 seconds duration was taken with a 
mean frame rate of 30 frames/s, and particle movement was analysed by NTA 
software (version 2.2, NanoSight). The NTA software is optimized to first identify and 
then track each particle ona frame-by-frame basis, and its Brownian movement is 
trackedand measured from frame to frame. The velocity of particlemovement is used 
to calculate particle size by applying the two-dimensional Stokes–Einstein equation. 
The range of sizes thatcan be analysed by NTA depends on the particle type: metal 
NPs, such as colloidal gold, have a highrefractive index while for cell-derived vesicles, 
like exosomes and microvesicles, the refractive index is very low and their smallest 
detectable size using theNTA system is approximately 50 nm [Gercel-Taylor et al., 
2012]. NTA post-acquisition settingswere optimized and kept constant between 
samples, and eachvideo was then analysed to give the mean, mode, and median 
vesicle size together with an estimate of the concentration. 
 
7.1.3 - Coating of microarray silicon chips with poly(DMA-NAS-MAPS) 
Poly(DMA-NAS-MAPS)-coated silicon microarrays were fabricated according to the 
protocol described in paragraph 5.1.2. Brieﬂy, silicon chips were immersed in a 
poly(DMA-NAS-MAPS) solution (1% w/v in 0.9 M (NH4)2SO4) for 30 min. The chips were 
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then rinsed with water, dried under nitrogen and cured for 15 min under vacuum at 
80° C [Cretich et al., 2009b]. 
 
7.1.4 - Direct immunoassays using IRIS and fluorescence-based detection platforms 
Purified standard exosomes peraprations were provided by collaborators from IRCSS – 
Fatebenefratelli (Brescia, Itay) as described in paragraph 7.1.1. 
Samples were at first diluted four times in pure PBS or in 2% paraformaldehyde (PFA) 
in PBS and printed on both uncoated and poly(DMA-NAS-MAPS)-coated silicon chips, 
with 100 and 500 nm oxide layer thickness, using a SciFlexArrayer S5 spotter from 
Scienion (Berlin, Germany). On the same chips, also a Goat anti-Rabbit IgG whole 
molecule was printed as reference together with the empty printing buffers as 
negative controls. Four replicate spots were patterned on each surface; in the 
experimental conditions used, the volume of the spotted drops was 400 pL. Printed 
chips were placed in a humid chamber and incubated overnight at room temperature. 
The copolymer-coated chips were then blocked with 50 mM ethanolamine solution in 
1 M TRIS/HCl pH 9 for 1 h. Both uncoated and coated chips were subsequently washed 
with water and dried under a stream of nitrogen. IRIS images were acquired and ﬁtted 
with Zoiray Acquire software. For each protein, signals from 4 replicate spots were 
averaged. 
Further uncoated and poly(DMA-NAS-MAPS)-coated silicon chips were arrayed with 
several dilutions (i.e. 1:2, 1:4, 1:8, 1:16, 1:32) of the same exosome samples in 2% PFA 
in PBS as printing buffer. Empty printing buffer was spotted as negative control while 
Cy3-labeled steptavidin (SA-Cy3) was used as reference for fluorescence acquisitions. 
Seven replicate spots were patterned according to the same spotting protocol 
described above. Also in this assay, printed chips were placed in a humid chamber and 
incubated overnight at room temperature. The copolymer-coated chips were then 
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blocked with 50 mM ethanolamine solution in 1 M TRIS/HCl pH 9 for 1 h. Both 
uncoated and coated chips were subsequently washed with water and dried under a 
stream of nitrogen. Chips were then incubated in static conditions for 2 hours with 
detection antibodies against the human tetraspanin CD63 (hCD63): Rabbit IgG from SBI 
(clone EXOEL-CD63A-1) or biotin-labeled Mouse IgG from Ancell (clone 215-030), 
BioLegend (clone H5C6) or ExBio (clone MEM-259). All detection antibodies were 
diluted to a final concentration of 1 ug/mL in incubation buffer (50 mM Tris/HCl, 150 
mM NaCl, 0.02% Tween-20 and 1% BSA). Chips were then washed with PBS for 10 min 
with stirring, rinsed with water and incubated in static conditions, for 1 hour, 
respectively with Cy3-labeled Goat anti-Rabbit IgG (GaR-Cy3) at 1 µg/mL or with Cy3-
labeled streptavidin (SA-Cy3) at 2 mg/mL in PBS. Chips were washed again with PBS 
and water for 10 min each, rinsed with water and dried under nitrogen stream. 
Fluorescence was determined by a ProScanArray scanner (PerkinElmer, Boston, MA), 
and silicon chips were analysed using 90% Photomultiplier (PMT) gain and laser power. 
The ﬂuorescence intensities of 7 replicate spots were averaged. 
 
7.1.5 - Sandwich immunoassays using IRIS and fluorescence-based detection platforms 
Capture IgG against hCD63, clone H5C6 (from BioLegend) and Cy3-labeled streptavidin 
(as reference) were arrayed on poly(DMA-NAS-MAPS)-coated silicon chips, with 100 
and 500 nm oxide layer thickness, using a SciFlexArrayer S5 spotter from Scienion 
(Berlin, Germany). Antibodies were printed at 1 mg/mL in 25 replicates; the volume of 
spotted drops was 400 pL. Printed chips were placed in a humid chamber and 
incubated overnight at room temperature. Then they were blocked with 50 mM 
ethanolamine solution in 1 M TRIS/HCl pH 9 for 1 h, washed with water and dried 
under a stream of nitrogen. IRIS images of printed capture antibodies were acquired 
with Zoiray Acquire software, before any incubation with exosome samples. 
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Purified exosomes standard samples were provided by collaborators from IRCCS- 
Fatebenefratelli (Brescia, Italy) as described in paragraph 7.1.1, and quantified using 
NanoSight measurements by partners from Prosperi’s laboratory at Bicocca Unuversity 
(Milan, Italy). Accordig to NTA quantification, exosomes were diluted in PBS to a 
concentration of 16, 4, 2, 1.6, 0.6, 0.4 and 0 E+10 particles/mL and then 20 uL of each 
suspension was incubated in static conditions for 2 hours on printed chips. After that, 
chips were washed with PBS with stirring, rinsed in water and dried under nitrogen 
stream. Further label-free IRIS images were acquired with Zoiray Acquire software, 
after the incubation with exosome samples. All IRIS files were fitted and processed 
using Zoyray Process software.The effective mass increase from captured exosomes on 
printed antibodies was obtained subtracting the signals measured before and after 
sample incubation. Net values from 25 spots were averaged to design a calibration 
curve. 
Chips were furthermore incubated in static conditions, for 1 hour, with 1 µg/mL (in 
incubation buffer, 1% BSA) of the selected biotin-labeled detection antibody against 
hCD63, clone H5C6 (from BioLegend). As vesicles display several tetraspanins on their 
membrane, a sandwich immunoassay is possible even when using the same 
monoclonal antibody for both capture and detection purposes. Chips were then 
washed with PBS for 10 min with stirring, rinsed with water and incubated in static 
conditions, for 1 hour, with Cy3-labeled streptavidin (SA-Cy3) at 2 mg/mL in PBS. Chips 
were washed again with PBS and water for 10 min each, rinsed with water and dried 
under nitrogen stream. Fluorescence was determined by a ProScanArray scanner 
(PerkinElmer, Boston, MA), and silicon chips were analysed using 70% or 80% 
Photomultiplier (PMT) gain and laser power. The ﬂuorescence intensities of 
25replicate spots were averaged to define a calibration curve. 
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7.1.6 - Indirect immunoassays using SP-IRIS detection platform 
Capture IgG against hCD63, clone H5C6 (from BioLegend) was arrayed, using a 
SciFlexArrayer S5 spotter from Scienion (Berlin, Germany), on poly(DMA-NAS-MAPS)-
coated silicon chips for SP-IRIS detector, characterized by 100 nm silicon oxide layer 
thickness on top and patterned with silicon references. The antibody was printed at 
0.5 mg/mL in 12 replicates; the volume of spotted drops was 400 pL. Printed chips 
were placed in a humid chamber and incubated overnight at room temperature. Then 
they were blocked with 50 mM ethanolamine solution in 1 M TRIS/HCl pH 9 for 1 h, 
washed with water and dried under a stream of nitrogen. IRIS images of printed 
capture antibodies were acquired with Zoiray Acquire software, before any incubation 
with exosome samples, in order to check spot morphology and quality. Then SP-IRIS 
images were acquired using a custom-made MGrid software running on MatLab. The 
instrument records the position of each spot of interest leading to quantification of 
single particles at the same positions before and after any incubation step. 
Afterwards, purified exosomes standard samples, provided by collaborators from 
IRCCS- Fatebenefratelli (Brescia, Italy) as described in paragraph 7.1.1, and quantified 
using NanoSight measurements by partners from Prosperi’s laboratory at Bicocca 
Unuversity (Milan, Italy), were diluted in PBS to a final concentration of 1.5 E+10 
particles/mL and 20 uL of this preparation were incubated on printed chips, overnight 
in static conditions. After that, chips were washed with PBS with stirring, rinsed in 
water and dried under nitrogen stream. Further label-free SP-IRIS images were 
acquired with the same procedure described above. Chips were furthermore 
incubated in static conditions, for 1 hour, with 40 nm gold nanoparticle-labeled 
detection antibody (NP(Au)-IgG) against hCD63, clone H5C6 (from BioLegend), at 1 
µg/mL, kindly provided by collaborators at Boston University. As vesicles display 
several tetraspanins on their membrane, a sandwich immnoassay is possible even 
when using the same monoclonal antibody for both capture and detection purposes. 
Chips were then washed again with PBS and water for 10 min each, rinsed with water 
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and dried under nitrogen stream. Final SP-IRIS measurements were acquired with the 
same instrumentation and protocol described above. Signals from 12 replicate spots 
were analysed and averaged. In order to measure the net single particle counts due to 
exosomes accumulation on each spot, the MGrid process software subtracted counts 
before from after exosomes incubation. Differently, in order to measure the the effect 
caused by the adding of nanoparticles, the software was set for gold scattering and 
subtracted counts before from after incubating with NP(Au)-IgG. 
 
7.1.7 - Indirect fluorescence detection of exosomes from human plasma samples 
Capture IgG against hCD63, clone H5C6 (from BioLegend) and Cy3-labeled streptavidin 
(as reference) were arrayed on a poly(DMA-NAS-MAPS)-coated silicon chip, with 100 
nm oxide layer thickness, using a SciFlexArrayer S5 spotter from Scienion (Berlin, 
Germany). The antibody was printed at 1 mg/mL in 80 replicates; the volume of 
spotted drops was 400 pL. Printed chip was placed in a humid chamber and incubated 
overnight at room temperature. Then it was blocked with 50 mM ethanolamine 
solution in 1 M TRIS/HCl pH 9 for 1 h, washed with water and dried under a stream of 
nitrogen. 
Human plasma from IRCSS Fatebenefratelli hospital (Brescia, Italy) bio-bank was 
thawed and simply centrifuged at 3000g. Part of the sample was characterized using 
NanoSight measurements by partners from laboratory of Prof. Prosperi at Bicocca 
University (Milan, Italy), while, as delivered, 20 uL of this plasma were incubated 
overnight at room temperature on the chip. After that, the chip was washed with PBS 
with stirring, rinsed in water and dried under nitrogen stream. The chip was 
furthermore incubated in static conditions, for 2 h, with 1 µg/mL (in incubation buffer, 
1% BSA) of the selected biotin-labeled detection antibody against hCD63, clone H5C6 
(from BioLegend). The chip was then washed with PBS for 10 min with stirring, rinsed 
with water and incubated in static conditions, for 1 hour, with Cy3-labeled streptavidin 
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(SA-Cy3) at 2 mg/mL in PBS. The chip was washed again with PBS and water for 10 min 
each, rinsed with water and dried under nitrogen stream. Fluorescence was 
determined by a ProScanArray scanner (PerkinElmer, Boston, MA), and silicon chips 
were analysed using 90% Photomultiplier (PMT) gain and laser power. The 
ﬂuorescence intensities of 80 replicate spots were averaged to define a calibration 
curve. 
 
 
7.2 - RESULTS AND DISCUSSION 
7.2.1 - Direct immunoassays for IRIS and fluorescence-based exosomes detection 
The firs step to set a feasible immunoassay able to detect exosomes as intact vesicles 
consisted in chosing the best experimental parameters and the best conditions to 
handle samples preserving their integrity during tests. For these reasons, in 
preliminary experiments, exosomes purified from human fibroblast cell culture were 
chosen as standard model. 
Direct immunoassays require the target biomolecules to be printed on the a proper 
surface and subsequently assayed by labelled detection antibodies. Thus, first of all, 
exosomes were diluted in two different printing buffers, respectively PBS and 2% 
paraformaldehyde (PFA), and arrayed on both uncoated and poly(DMA-NAS-MAPS)-
coated silicon chips with 100 or 500 nm silicon oxide layer thickness. IRIS acquisitions 
of the printed material did not show any spot when using PBS as printing buffer, while 
the fixation of membranes by PFA increased vesicles capability to bind the surface, 
thus providing the visible spots reported the central line of Figure 7.4. In the same 
picture, the first line corresponds to the printing buffer only (2% PFA in PBS), 
demonstrating that there are no artifacts in the biomass measurements due to the 
printing solution. On the contrary, the third line shows highly contrasting spots 
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corresponding to 1 mg/mL IgG (goat anti-rabbit IgG), that has been used as internal 
reference for focusing during acquisitions. 
 
 
 
Figure 7.4 - LowMag-IRIS images of uncoated and poly(DMA-NAS-MAPS)-coated 
silicon chips, spotted in 2% PFA in PBS (central line); printing buffer was spotted as 
blank control (first line) and Goat anti-Rabbit IgG was spotted as reference. 
 
 
Figure 7.5 reports the quantification of IRIS signals in terms of thickness increase on 
each spot of interest from the first and second line, on both surfaces. Confirming what 
discussed above, the printing buffer itself does not provide any signal, while a 
significative increase is measured on printed exosomes. Moreover, higher values were 
detected on the uncoated surface rather than on the poly(DMA-NAS-MAPS)-coated 
one, likely due to hydrophobic interactions between the lipidic vesicles and bare silicon 
which facilitate vesicle binding on the surface. 
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Figure 7.5 - Quantification of LowMag-IRIS signals, measured in terms of thickness 
increase (nm) on the silicon surfaces due to biomass accumulation. Green bars 
refers to signals on uncoated chip; pink bars represent signals fron poly(DMA-
NAS-MAPS)-coated chip. 
 
 
Figure 7.6 summarizes the workflow of the direct assay development. As outlined, 
after IRIS measurements, chips printed with several exosomes dilutions, in 2% PFA, 
were further incubated with labeled antibodies for fluorescence detection. In order to 
detect whole vesicles through fluorescence detection, antibodies against membrane 
proteins are required. Among all proteins known as EV markers, the human 
tetraspanin CD63 (hCD63) was selected. Four different antibodies were tested in a 
two-step incubation assay. First the antibody (Rabbit IgG from SBI or biotin-labeled 
Mouse IgG from Ancell, BioLegend and ExBio) were incubated, then a secondary 
reporter was added (respectively, a secondary Goat anti-Rabbit IgG-Cy3 or 
streptavidin-labeled Cy3). 
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Figure 7.6 – Direct immunoassay workflow. First, exosomes were spotted on uncoated 
silicon chips, using 2% PFA in PBS as printing buffer and label-free IRIS detection was 
used to quantify the total amount of printed biomaterial per spot. Later, chips were 
further incubated with antibodies against hCD63 and detected using a fluorescent 
reporter (SA-Cy3 or Goat anti-Rabbit IgG-Cy3). Fluorescence detection revealed hCD63-
positiveprinted vesicles. 
 
 
  
 111 
Images from each tested condition are reported in Figure 7.7. It is clearly evident that 
also fluorescence detection provides higher signals on uncoated chips (right column of 
panel b) as compared to poly(DMA-NAS-MAPS)-coated ones (left column of panel b), 
corroborating the idea of a higher binding capability on hydrophobic surfaces. 
Among all tested antibodies, only signals from antibodies from SBI and BioLegend were 
detectable. However, the first one was not specific as higher fluorescence was 
detected on negative control and lower vesicle concentration rather then higher. On 
the opposite, the Mouse biotin-labed IgG to hCD63 from BioLegend (clone H5C6) was 
the only one able to provide linear and specific signals on printed exosomes, expecially 
on uncoated silicon chips. Thanks to its performances this clone was chosen for further 
investigations. The combination of information provided by direct detection is still not 
sufficient to provide phenotiping and size distribution of this kind of vesicles. Thus, 
once a protocol to handle exosomes was established and based on the selected 
antibody clone, indirect sandwich immunoassays were developed. 
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a) 
SA-Cy3 Exosomes diluted 1:2 in 2% PFA/PBS (7 spots) 
SA-Cy3 Exosomes diluted 1:4 in 2% PFA/PBS (7 spots) 
SA-Cy3 Exosomes diluted 1:8 in 2% PFA/PBS (7 spots) 
SA-Cy3 Exosomes diluted 1:16 in 2% PFA/PBS (7 spots) 
SA-Cy3 Exosomes diluted 1:32 in 2% PFA/PBS (7 spots) 
SA-Cy3 [Negative control] 2% PFA/PBS (7 spots) 
 
b)
 
Figure 7.7 - Selection of anti-hCD63 detection antibody on fluorescence microarrays. a) 
Spotting scheme. b) fluorescence images (90% laser power and PMT gain) on poly(DMA-
NAS-MAPS)-coated and uncoated chips, respectively on the left and right column. Per 
each line detection with four diffeernt antibodies are reported. The best performances 
are given by the biotinylated Mouse anti-hCD63 IgG from BioLegend, coupled with 
Cyanine 3 labeled with streptavidin (SA-Cy3). 
 
 
7.2.2 - Sandwich immunoassays forIRIS and fluorescence-based exosomes detection 
After establishing a protocol for exosomes purified from human fibroblast cell culture 
and following the selection of an antibody with high sensitivity and specificity (clone 
H5C6 from BioLegend), a sandwich immunoassay was developed. As reported in Figure 
7.8, exosomes were captured by antibodies printed on the poly(DMA-NAS-MAPS)-
coated silicon chips and then detected using the conventional label-free IRIS platform. 
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Figure 7.8 – Sandwich immunoassay workflow. First, capture antibodies were printed on 
poly(DMA-NAS-MAPS)-coated silicon chips and IRIS measurements of background 
signals were acquired before any incubation. Then several sample dilutions were 
incubated in static conditions for 2 h and further IRIS images were acquired in order to 
detect the net signal increase due to exosomes bound to their capture antibodies. Later, 
the same chips were incubated with biotin-labeled antibody against hCD63 (clone H5C6, 
from BioLegend) and detected using Cy3-labeled streptavidin as fluorescence reporter. 
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The net signal from exosomes bound to their specific antibodies was obtained 
subtracting the measurements after the sample incubation from the one before it. 
According to the NanoSight quantifications, several sample dilutions were tested to 
obtain the curve reported in Figure 7.9.  
 
 
 
Figure 7.9 – Conventional IRIS measurements of exosomes bound to capture antibodies 
(against hCD63, clone H5C6, from BioLegend) printed on the poly(DMA-NAS-MAPS)-
coated silicon chips. a) Signals from samples with more than 1.6 E+10 exosomes/mL 
reach the plateau as a consequence of saturation of binding sites on each spot of 
interest. b)Close-up of the linear range from 0 to 1.6 E+10 exosomes/mL. 
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Samples from 0 to 1.6 E+10 particles/mL shows a linear correlation between the 
incubated vesicles and the biomass measured on the capture antibodies, 
demonstrating the capability to capture and quantify exosomes in a label-free fashion. 
On the contrary, samples with more than 1.6 E+10 exosomes/mL do not provide any 
thickness increase on the spots. This is likely due to the saturation of printed capture 
antibodies, as a consequence of steric hindrance or depletion of available binding sites. 
Moreover, as vesicles display several hCD63 tetraspanins on their membrane, a 
sandwich immunoassay is possible even when using the same monoclonal antibody for 
both capture and detection purposes. Thus, as reported in Figure 7.8, chips were 
further incubated with the selected biotin-labeled antibody to hCD63, clone H5C6 
(from BioLegend) and subsequently detected using Cy3-labeled streptavidin as 
fluorescence reporter. Signals were revealed and quantified using 70% laser power and 
PMT gain. A calibration curve was obtained in a linear range from 0 to 4.0 E+10 
particles/mL (Figure 7.10).  
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Figure 7.10 – Fluorescence signals (70% laser power and PMT gain) from exosomes 
captured and detected using antibodies against hCD63 (clone H5C6, from BioLegend) 
in a sandwich immunoassay format. 
 
 
Label-free IRIS and Fluorescence detection provided complementary information: the 
first reports the total amount of biomass bound to the spots of interest while the latter 
provides biological data. For instance, in the proposed assay, hCD63-positive exosomes 
were detected leading to the possibility of phenotyping vesicles in a given sample. In 
order to corroborate the feasibility of this tool, the signals from both measurements, 
in the common range from 0 to 1.6 E+10 exosomes/mL, were plot on a single graph 
(Figure 7.11), demonstrating a good correlation factor between the two analytical 
platforms. 
It would be of great interest to improve this tool printing a cocktail of capture 
antibodies against several exosome biomarkers. This would enhance the vesicle 
capturing yield in a given sample, allowing the detection of the total amount of bound 
biomaterial as well as to phenotype it by incubating with differential detection 
antibodies, specific for a given tissue or pathology biomarker.  
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Figure 7.11 – Correlation between IRIS (x axis) and fluorescence (at 70% laser power and 
PMT gain, y axis) detection platforms. 
 
 
7.2.3 - Indirect detection of intact exosomes as singleparticles using SP-IRIS platform 
Although the integration of data collected from IRIS and fluorescence detection 
platforms provided an innovative tool for detection and characterization of exosomes, 
still they do not characterize the size distribution of vesicles in a given sample, which is 
an information of paramount importance as exosomes are not defined only based on 
biomarkers expressed on their surface, but also on their size. For this reason, further 
investigations were performed at the Electrical and Computer Engineering Department 
at Boston University (MA, USA), where the team of Prof. S. Unlu had developed a label-
free detection platform called Single particle IRIS (SP-IRIS), which is a recent evolution 
of the conventional IRIS to enable digital detection of nanoparticles (NPs) on surface 
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with unique orthogonal verification via size/shape discrimination and minimal sample 
preparation. 
As described in the Chapter 3 (paragraph 3.2.2), the detection principle of SP-IRIS is 
based on the enhanced contrast in the scattering signal from particles on a layered 
substrate. To detect and size nanoparticles (NPs), IRIS shines light from visible LED 
sources on NPs bound to the sensor surface, which consists of 100 nm silicon dioxide 
layer on top of a silicon substrate. Interference of light reflected from the sensor 
surface is modified by the presence of particles producing a distinct signal that reveals 
the size of the particle itself. In this approach the dielectric layered structure acts as an 
optical antenna optimizing the elastic scattering characteristics of NPs for sensitive 
detection and analysis. The instrument is set for low-index dielectric particles with 
diameters of 60 to 200nm and metallic (Au and Ag) NPs with diameters ranging from 
20 to 100nm [Yurt et al., 2012]. 
Originally, Daaboul and colleagues applied this platform to detect virus particles in 
complex samples. Considering the virions as NPs allowed the size discriminations and 
differentiation between wild-type and modified particles, demonstrating also the 
simultaneous detection of multiple viruses in serum or whole blood as well as in 
samples contaminated with high levels of bacteria [Daaboul et al., 2014]. By employing 
affinity-based capture, size discrimination and a “digital” detection scheme to count 
single virus particles, they showed that a robust and sensitive virus/NP sensing assay 
could be established for targets in complex samples.Based on their physical properties, 
exosomes do not exhibit distinct spectral resonances in the visible spectral region and 
have low refractive index contrast with respect to the background, making their 
detection difficult comparing to similar size metallic nanoparticles under resonance. 
However, exosome samples were analysed using SP-IRIS in a fashion similar to the one 
described for viruses. As depicted in Figure 7.12, individual exosomes were captured 
using a commecial antibody against the tetraspanin hCD63, arrayed on the surface of 
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silicon chips. Spot quality and antibody density was characterized using the total 
biomass measurement modality of conventional IRIS. The chips were then incubated 
with samples and the surface accumulation of exosomes was observed in dry 
conditions. The advantage of the dry measurements is the improved visibility; the 
refractive index of exosomes is low and their contrast (visibility) in liquid would have 
been further reduced. 
 
 
Figure 7.12  - Indirect immunoassay workflow using SP-IRIS detection platform. First, capture 
antibodies were printed on poly(DMA-NAS-MAPS)-coated silicon chips and IRIS analysis of spot 
quality was performed before any incubation. Then SP-IRIS images were acquired to measure 
background particle counts and to record spot positions on the chip. Afterwards, exosomes 
were incubated in static conditions overnight and further SP-IRIS images were acquired in 
order to detect the net signal increase due to exosomes bound to their capture antibodies. 
Later, the same chips were incubated again with gold nanoparticle-labeled antibody ((Au)NP-
IgG) against hCD63 (clone H5C6, from BioLegend) and final SP-IRIS measurements were 
performed in order to evaluate the binding of labeled antibodies to capture exosomes. 
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Data collected in dry conditions at end-point, as shown in Figure 7.13, demonstrate 
the capability of the technology to detect exosome particles. Exosomes from a 
population with size distribution of 60-100nm in diameter are already distinguishable 
from the background, however for their accurate quantification and size 
discrimination, further system improvements need to be implemented. Later, the 
same chips were further incubated with secondary antibodies (still against hCD63) 
labelled with 40nm gold nanoparticles (Au-NP) and imaged again under dry conditions. 
A significant shift in the size distribution shows that many of the previously captured, 
detected and sized exosomes are decorated with Au-NP indicating their affinity to the 
particular antibody. 
Further experiments will aim at multiplexing array formats to provide incubations with 
different secondary antibodies labeled with Au-NP, for phenotyping exosomes based 
on the presence of specific surface antigens. 
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Figure 7.13  - SP-IRIS detection of whole exosomes as single particles. The graph at the 
top reports the size distribution of particles count on each spot of interest. The blu bars 
correspond to counts on printed antibodies, as a pre-incubation background. The red 
bars indicate the total counts on spots after sample incubation, due to exosomes 
captured on their specific antibodies; it is clearly evident that vesicles under study are 
exosomes as their size distribution stands within 50 and 100 nm of diameter. Moreover, 
green bars correspond to measurements after incubation with gold nanoparticles-
labeled antibodies, leading to a shift in the size distribution as a consequence of 
exosomes decorated by detection IgG. Pictures under the graph are example of images 
acquired by SP-IRIS detector: printed capture antibodies (pre-incubation), after 
exosomes incubation (Direct exosomes detection), and after incubation with gold 
nanoparticles-labeled IgG. NP, both vesicles and gold, are visible as white dots, thanks to 
their contrast during scattering of incident light. 
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7.2.4 - Indirect fluorescence detection of intact exosomes from human plasma samples 
The sandwich immunoassay developed as described above, was validated using real 
samples of clinical interest in order to detect exosomes in biological fluids without the 
need of time-consuming purification protocols. 
For this reason, a human plasma sample form the IRCSS Fatebenefratelli hospital bio-
bank (Brescia, Italy) was assayed. Frozen plasma was thawed and simply centrifuged at 
3000g, then NanoSight measurements estimated the exosomes content in 1.31 E+10 
particles/mL. Microarray experiment required the overnight incubation of 20 uL of 
plasma in static condition. Exosomes captured on spotted antibodies were then 
detected by fluorescence using the anti hCD63 selected biotin-labeled antibody, 
coupled with Cy3-labeled streptavidin. Figure 7.14 shows fluorescence (at 90% laser 
power and PMT gain) from hCD63-positive vesicles in the tested sample.  Signals from 
80 spots were averaged, as reported in the graph below. 
 
 
 
Figure 7.14 – Fluorescence detection (at 90% laser power and PMT gain) and 
quantification of corresponding signals from hCD63-expressing exosomes in human 
plasma sample. 
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It is noticeable how, at comparable exosomes concentration of about E+10 
particles/mL, the signals from exosomes in plasma are lower than the signals detected 
for samples purified from cell culture and resuspended in PBS. In the case of plasma 
samples it was necessary to increase the laser power in order to improve the signal-to-
noise ratio. Figure 7.15 reports the comparison of fluorescence detection when using 
90% laser power and PMT gain for both plasma and standard exosome preparations. In 
this latter case signals are more than ten times higher, most likely due to the presence 
of many proteins and factors in the unpurified plasmawhich prevent the efficient 
binding of hCD63-positive vesicles, making it a very complex buffer. 
 
 
Figure 7.15 - Fluorescence detedction (at 90% laser power and PMT gain) of exosomes 
incubated overnight in static conditions at comparable concentration, as estimated by 
NanoSight measurements, respectively 1,31E+10 particles/mL in human plasma and 
6,38E+09 particles/mL in the standard purified preparation. Orange bar corresponds to 
signals from exosomes in human plasma sample, while the green bar shows the intensity 
of signals from the standard purified exosome preparation. It is evident that purification 
removes many proteins and factors which may interact with printed antibodies, 
preventing the capture of target vesicles. 
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7.3 - CONCLUSIONS 
Exosomes are small vesicles, defined based on their size (40–100 nm) and density 
(1.12-1.19 g/ml), released during cell differentiation as a consequence of 
multivesicular endosome fusion with the plasma membrane. These vesicles, enriched 
in several cell-derived factors such as proteins like the tetraspanin CD63 [Record et al., 
2011], have been isolated from different body fluids. In particular, many cells of the 
nervous system have been shown to release extra-cellular vesicles (EVs), implicating 
their active roles in development, function, and pathologies of this system and, more 
specifically, exosomes from CSF can be considered as carriers of biomarkers for 
neurological disorders [Lachenal et al., 2011].  
Up to now, due to their physical properties, it is very difficult to distinguish and 
characterize exosomes among all EVs in biological samples and for these reasons a 
major ongoing challenge is to establish methods to discriminate between exosomes 
and other types of vesicles [Bobrie et al., 2011].  As a consequence, a method to 
simultaneously detect, size and phenotype intact EVs is needed, by combining both 
accurate qualitative and quantitative analysis. The present study shows an innovative 
microarray platform which combines the information from label-free conventional and 
Single Particle IRIS with the fluorescence-based detection in order to analyse exosomes 
without disrupting their membranes. 
Exosomes from standard preparations of purified vesicles from human fibroblast cell 
culture were at first analyzed by NTA; then vesicles have been characterized through 
both direct and sandwich immunoassay formats. The monoclonal antibody against the 
biomarker hCD63, clone H5C6 from BioLegend, was chosen for its specificity and 
affinity to the target and was then used for both capture and detection of hCD63-
positive vesicles. Conventional IRIS measurements allowed to quantify the total 
amount of biomaterial on each spot of interest, which means the amount of vesicles 
captured by the printed antibodies. Moreover, these vesicles were also detected as 
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single nanoparticles using SP-IRIS, showing a size distribution between 60 and 100 nm 
which confirmed their being exosomes. Further SP-IRIS and fluorescence detection of 
hCD63 biomarker proved their identity and the vesicle integrity. 
Tests were performed on human plasma samples, in order to validate the detection 
tool also when exosomes are in a more complex matrix. Sandwich fluorescence-based 
immunoassays allowed the detection of hCD63-expressing nano-vesicles. However, 
further studies will aim at multiplexing the assay, searching at the same time for 
different biomarkers expressed on the surface of exosomes while characterizing them 
by the size distribution of bound particles. 
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APPENDIX 
 
 
 
Research paper publications regarding the development of protein microarrays for 
diagnostics applications are here reported: 
 
· Cretich M., Torrisi M., Daminelli S., Gagni P., Plavisch L. and Chiari M., Flow-
through, viral co-infection assay for resource-limited settings. Talanta (2014), in 
press. 
 
· Cretich M., Galati C., Renna L., Condorelli G.G., Gagni P. and Chiari M., 
Characterization of a new fluorescence-enhancing substrate for microarrays with 
femtomolar sensitivity. Sensors and Actuators B Chemical (2014), 192, 15–22. 
 
· Cretich M., Sola L., Gagni P. and Chiari M., Novel fluorescent microarray platforms: 
a case study in neurodegenerative disorders. Expert Review of Molecular 
Diagnostics (2013), 13(8), 863-73. 
 
· Gagni P., Sola L., Cretich M. and Chiari M., Development of a high-sensitivity 
immunoassay for amyloid-beta 1-42 using a silicon microarray platform. 
Biosensors & bioelectronics (2013), 47C, 490-495. 
 
· Sola L., Gagni P., Cretich M. and Chiari M., Surface immobilized hydrogels as 
versatile reagent reservoirs for microarrays. Journal of immunological methods 
(2013), 391(1-2), 95-102. 
 
· Peri C., Gagni P., Combi F., Gori A., Chiari M., Longhi R., Cretich M. and Colombo G., 
Rational Epitope Design for Protein Targeting. ACS Chemical Biology (2012); 8(2), 
397-404.  
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